Original Text
stringlengths 700
195k
| Summary
stringclasses 1
value |
|---|---|
**Title:** Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment (NCT00072579)
**Summary:** RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia.
PURPOSE: This phase II trial is studying sargramostim to see how well it works in treating patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic remission after initial treatment.
**Status:** COMPLETED
Study Phase: PHASE2
**Conditions:** Leukemia
Intervention(s) Tested: BIOLOGICAL: sargramostim
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Cytogenetic response (complete and partial)
The Secondary outcome measures of this study:
Toxicity as assessed by the Expanded Common Toxicity Criteria v2.0|Time to progression|Survival
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** N/A
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Wake Forest University Health Sciences
**Study Collaborator(s):** National Cancer Institute (NCI)
**Study Dates:**
Start Date: 2003-05
Primary Completion Date: 2006-04
Completion Date: 2007-12
First Posted: 2003-11-05
**Study Location(s):**
CCOP - Western Regional, Arizona, Phoenix, Arizona, 85006-2726, United States|CCOP - Bay Area Tumor Institute, Oakland, California, 94609-3305, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, 30165, United States|CCOP - Central Illinois, Decatur, Illinois, 62526, United States|Kentuckiana Cancer Institute, PLLC, Louisville, Kentucky, 40202, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, 70112, United States|Alamance Cancer Center, Burlington, North Carolina, 27216, United States|Hugh Chatham Memorial Hospital, Elkin, North Carolina, 28621, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, 27534-9479, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, 27858, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, 27157-1096, United States|CCOP - Columbus, Columbus, Ohio, 43206, United States|Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, 29615, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, 29303, United States | |
**Title:** Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS (NCT00517179)
**Summary:** The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Prostatic Hyperplasia|Impotence
Intervention(s) Tested: DRUG: Vardenafil 10mg
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo, From half hour prior to till six hour after administration of the drug (baseline)
The Secondary outcome measures of this study:
Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP), From half hour prior to till six hour after administration of the drug (baseline)|Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug, From half hour prior to till six hour after administration of the drug (baseline)
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: MALE
**Enrollment:** 40.0
**Funder Type:** OTHER_GOV
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Hospital Authority, Hong Kong
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2006-04
Primary Completion Date: N/A
Completion Date: 2007-05
First Posted: 2007-08-16
**Study Location(s):**
Prince of Wales Hospital, Hong Kong, China | |
**Title:** Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article (NCT00812279)
**Summary:** The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.
The main objective of this study is to compare the biomarkers of exposure to cigarette smoke constituents in smokers switching to SMAR and to biomarkers in smokers of conventional cigarettes (CC). The biomarkers of exposure will be measured in blood and urine samples collected from the subjects. Moreover, the biomarkers in subjects smoking conventional or SMAR cigarettes will be compared with those biomarkers in smokers who stop smoking for 5 days. The short term safety of this new product will also be evaluated.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Smoking
Intervention(s) Tested: OTHER: Distillation based smoking article (SMAR cigarette)|OTHER: conventional cigarette|OTHER: smoking cessation
**Outcome Measures of the Study:**
The primary outcome measures of this study:
To demonstrate a reduction in the three primary biomarkers of exposure: Carboxyhaemoglobin concentration in blood, Urinary excretion of S-phenylmercapturic acid and urinary excretion of NNAL and NNAL-glucuronides (total NNAL), 5 days
The Secondary outcome measures of this study:
To explore changes from baseline COHb, S-PMA, and total NNAL in the three study arms in the course of the study, 5 days|To explore changes from baseline in the three study arms with regard to urinary excretion of biomarkers of exposure to several other smoke constituents., 5 days|To assess urinary excretion of nicotine and its five major nicotine metabolites in the three study arms, 5 days|To assess nicotine and cotinine concentrations in plasma in the three study arms To compare levels of all biomarkers of exposure in the SMAR arm to those in the smoking cessation (SC) arm, 5 days|To assess the mutagenicity potential in urine at the end of the study in the three study arms, 5 days|To monitor blood pressure, pulse rate, electrocardiogram, clinical laboratory parameters (standard clinical biochemistry, standard haematology and urine analysis), and adverse events, 5 days|To investigate craving and withdrawal symptoms as well as pulmonary symptoms in all three study arms by means of questionnaires, 5 days|To investigate change in cytochrome P450 1A2 (CYP1A2) activity from D0 to D5 in the three study arms, 5 days|To assess and compare human smoking topography (HST) in smokers before and after switching to SMAR, 5 days
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT
ii) Sex: ALL
**Enrollment:** 112.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
**Study Sponsor(s):** Philip Morris Products S.A.
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2008-11
Primary Completion Date: 2009-02
Completion Date: 2009-02
First Posted: 2008-12-22
**Study Location(s):**
MTZ Clinical Research Inc., Warsaw, 02-106, Poland | |
**Title:** Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN (NCT03878979)
**Summary:** Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).
**Status:** COMPLETED
Study Phase: PHASE2
**Conditions:** Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Cancer Metastatic
Intervention(s) Tested: DRUG: Nivolumab 480mg and surgical resection
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Safety as measured by number of participants with drug-related adverse events, Safety of neoadjuvant nivolumab administration in patients with newly diagnosed head and neck cancer and those with locoregional recurrence or oligometastatic disease undergoing surgical resection measured by number of participants with drug related adverse events as defined by CTCAE v5.0, occurring up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer), Up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer)|Feasibility as measured by number of participants with successful completion of preoperative treatment and no extended treatment-related delays, Feasibility of neoadjuvant nivolumab administration in patients with newly diagnosed head and neck cancer and those with locoregional recurrence or oligometastatic disease undergoing surgical resection, measured by number of participants with successful completion of preoperative treatment and proceeding to surgery without any extended treatment related delays more than > 28 days from pre-planned day 0., Up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer)
The Secondary outcome measures of this study:
Major pathologic response rate, Number of participants with < 10% residual tumor in the resection specimen., Day 0 (after surgery)|Progression free survival (PFS), Number of months until radiologic or clinical progression or death, whichever occurs first., up to 3 years|Radiographic response rate, Number of participants with response as determined by RECIST version 1.1 and immune-related response criteria (irRC). Per RECIST criteria, Complete response (CR) is a disappearance of all target lesions, Partial response (PR) is >= 30% decrease in the sum of the largest diameter (LD) of target lesions, Progressive disease (PD) is >= 20% increase in the sum of the LD of target lesions.
Per irRC, immune-related Complete Response (irCR) is the disappearance of all lesions, measured or unmeasured, and no new lesions; an immune-related Partial Response (irPR) is a 50% drop in tumour burden from baseline as defined by the irRC; and immune-related Progressive Disease (irPD) is a 25% increase in tumour burden from the lowest level recorded., up to 4 weeks post-intervention
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 26.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
**Study Sponsor(s):** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
**Study Collaborator(s):** Bristol-Myers Squibb
**Study Dates:**
Start Date: 2019-07-08
Primary Completion Date: 2023-10-17
Completion Date: 2023-10-17
First Posted: 2019-03-18
**Study Location(s):**
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States | |
**Title:** Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents (NCT05602779)
**Summary:** Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence.
Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.
**Status:** RECRUITING
Study Phase: N/A
**Conditions:** Self Harm|Suicidal Ideation
Intervention(s) Being Tested: DEVICE: tVns Program|OTHER: Phone App Program|COMBINATION_PRODUCT: tVNS and Phone App Program|OTHER: Enhanced Treatment as Usual
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days, Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge.
All participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms., 30 Days|Improved Reports of Social Isolation and Loneliness, Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen.
Some teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teens self-reported feelings of isolation and loneliness.
For the rate of change, we will use percentile ranking vis-a-vis national norms., 30 Days|Improved Results from Participants Typical Treatment, Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm.
For the rate of change, we will use percentile ranking vis-a-vis national norms., 30 Days
The Secondary outcome measures of this study:
Adherence to tVNS and Phone App intervention from Baseline to 30 days., Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app., 30 Days
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 212.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
**Study Sponsor(s):** University of Notre Dame
**Study Collaborator(s):** University of Rochester
**Study Dates:**
Start Date: 2023-10-08
Primary Completion Date: 2027-04-15
Completion Date: 2027-09-30
First Posted: 2022-11-02
**Study Location(s):**
University of Notre Dame, South Bend, Indiana, 46617, United States | |
**Title:** Genistein in Treating Patients With Prostate Cancer (NCT01126879)
**Summary:** RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.
**Status:** TERMINATED
Study Phase: PHASE2
**Conditions:** Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage II Prostate Cancer|Stage III Prostate Cancer
Intervention(s) Tested: DIETARY_SUPPLEMENT: genistein|OTHER: placebo|PROCEDURE: therapeutic conventional surgery
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs, Blood will be collected to analyze the number of CPCs at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery., At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery
The Secondary outcome measures of this study:
Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy, Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery., At baseline, 1 and 12 months after surgery|Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue, At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue., At baseline and at time of surgery|Measurement of PSA in Serum and Plasma by Nanotechnology, Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery., At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: MALE
**Enrollment:** 12.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** Northwestern University
**Study Collaborator(s):** National Cancer Institute (NCI)
**Study Dates:**
Start Date: 2011-02-03
Primary Completion Date: 2013-05-09
Completion Date: 2013-12-28
First Posted: 2010-05-20
**Study Location(s):**
Northwestern University, Chicago, Illinois, 60611, United States | |
**Title:** Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease (NCT05865379)
**Summary:** The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:
* Is BUFY01 non-inferior to SVS20 in terms of signs of DED?
* Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED?
Participants will be asked to:
* Visit the trial site at 4 different timepoints
* Use the allocated study treatment everyday until the end of the study (during 3 months)
* Be examined by the investigator
* Complete several questionnaires
* Return unused study treatment.
Researchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.
**Status:** NOT_YET_RECRUITING
Study Phase: N/A
**Conditions:** Dry Eye Disease
Intervention(s) Being Tested: DEVICE: BUFY01 eye drops in single-dose containers|DEVICE: SVS20 eye drops in single-dose containers
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Signs, Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome), Day 28
The Secondary outcome measures of this study:
Symptoms, Change from baseline in Ocular Surface Disease Index, Day 28
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 80.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** TRB Chemedica International SA
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2024-03
Primary Completion Date: 2025-10
Completion Date: 2025-10
First Posted: 2023-05-18
**Study Location(s):**
N/A | |
**Title:** Caudal Dexmedetomidine Analgesia in Pediatrics . (NCT03791879)
**Summary:** Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration) in providing pain relief over a 24-h period and lowest surgical stress peak. Study hypothesis: Levobupivacaine 0.125 %( ED95) combined with different increasing doses of dexamedatomedine >1 µg/kg could not add more analgesic & stress response obtundation outcome, but increase side effects (sedation and hemodynamic depression). The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour. Aim of the Study: To detect the optimal analgesic and safe caudal adjuvant DEXM dose associated with the least side effects& stress response modulation, guided by PO Cortisol peak difference in between the study groups during pediatric hypospadias surgery.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal Block
Intervention(s) Tested: DRUG: Caudal dexamedatomidine analgesia
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Time to (1st analgesic request objective pain score (OPS) ≥4), time from full recovery till child express moderate pain OPS 4 and ask for the first analgesic dose, Basal (0) till 24 hours.
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: MALE
**Enrollment:** 164.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE
**Study Sponsor(s):** Mansoura University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-01-01
Primary Completion Date: 2020-10-01
Completion Date: 2020-10-15
First Posted: 2019-01-03
**Study Location(s):**
Anesthesia department,Faculty of medicine, Mansoura univerisety, Mansoura, Egypt | |
**Title:** The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients (NCT03877679)
**Summary:** Introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the management of Oral lichen planus.
* Assess the efficacy of this preparation on pain, clinical parameter and the level of IL-33 in saliva.
* Compare the outcome of new preparation with the gold standard treatment (corticosteroids).
**Status:** UNKNOWN
Study Phase: PHASE1
**Conditions:** Oral Lichen Planus
Intervention(s) Being Tested: DRUG: Triamcinolone|DRUG: Turmeric paste
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Pain intensity, measured by Visual Analog Scale (VAS) 0 = no pain 10= severe pain 0= no pain 10= pain severe pain, 4 weeks
The Secondary outcome measures of this study:
clinical sign score, measured by Thongprasom from score 0 to 5 0= only white lesion 5=area of erosion more than 2 cm, Baseline , 2nd week and 4th week|IL-33 level in saliva, by ELISA, base line and 4th week
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD, ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 40.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** Cairo University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-05-01
Primary Completion Date: 2020-05-01
Completion Date: 2020-06-01
First Posted: 2019-03-18
**Study Location(s):**
N/A | |
**Title:** DNA Methylation for Screening Uterine Cervical Lesions (NCT03960879)
**Summary:** The primary objective of this study is to compare the testing of DNA methylation, high-risk HPV subtypes, and cytology with the definite histological results for uterine cervical lesions in a prospective cohort study.
This study will include 300 unselected patients with definite histological results. All the cervical specimens of cytology collected in the clinical settings will be utilized for the testing of DNA methylation, high-risk HPV subtypes and thin prep liquid-based cytology test (TCT). The sensitivity, specificity, positive predictive value and negative predictive value were calculated based on the known histological results. The differences of DNA methylation with high-risk human papillomavirus (HPV) and TCT will also be analyzed.
The testing of DNA methylation will be performed with the methylation-specific polymerase chain reaction (PCR). The TCT and HPV testing will be performed with the Roche kits.
**Status:** UNKNOWN
Study Phase: N/A
**Conditions:** DNA Methylation|Uterine Cervical Cancer|High Grade Squamous Intraepithelial Lesions|Low Grade Squamous Intraepithelial Lesions
Intervention(s) Being Tested: DIAGNOSTIC_TEST: DNA methylation|DIAGNOSTIC_TEST: High-risk HPV|DIAGNOSTIC_TEST: TCT
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Sensitivity of DNA methylation, Sensitivity of DNA methylation compared with histological results for the differentiation of cervical cancer and high grade squamous intraepithelial lesions (HSIL), 1 year|Specificity of DNA methylation, Specificity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL, 1 year
The Secondary outcome measures of this study:
Positive predictive value of DNA methylation, Positive predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL, 1 year|Negative predictive value of DNA methylation, Negative predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL, 1 year|Correlation coefficient of DNA methylation with other screening methods, Correlation coefficient of DNA methylation with high-risk HPV and TCT results, 1 year
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: FEMALE
**Enrollment:** 300.0
**Funder Type:** OTHER
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** Lei Li
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-06-01
Primary Completion Date: 2020-06-01
Completion Date: 2020-06-01
First Posted: 2019-05-23
**Study Location(s):**
Lei Li, Beijing, Beijing, 100730, China | |
**Title:** Study Comparing the MiStent SES Versus the XIENCE EES Stent (NCT02385279)
**Summary:** The primary objective of this study is to compare the performance of MISTENT to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Coronary Stenosis
Intervention(s) Tested: DEVICE: MiStent|DEVICE: XIENCE EES
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE), DOCE is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and clinically-indicated target lesion revascularization., 12 months postprocedure
The Secondary outcome measures of this study:
POCE, POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization, At 12 months|MACE, MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR), At 12 months|Target Vessel Failure (TVF), Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically indicated TVR, At 12 months|All-cause Death, All-cause death, At 12 months|Myocardial Infarction, Any Myocardial infarction, At 12 months|Any Revascularization, Any revascularization, At 12 months|Stent Thrombosis, Definite or probably stent thrombosis according to ARC, At 12 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 1398.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
**Study Sponsor(s):** ECRI bv
**Study Collaborator(s):** Micell Technologies|Stentys
**Study Dates:**
Start Date: 2015-03-20
Primary Completion Date: 2017-01-31
Completion Date: 2021-02-04
First Posted: 2015-03-11
**Study Location(s):**
Research Center Corbeil, Corbeil, France|Research Center Nimes, Nimes, France|Research Center Poitiers, Poitiers, France|Research Center Jena, Jena, Germany|Research Center Leipzig, Leipzig, Germany|Research Center Munster, Munster, Germany|Research Center Ulm, Ulm, Germany|Research Center Wiesbaden, Wiesbaden, Germany|Research Center Amersfoort, Amersfoort, Netherlands|Research Center Amsterdam, Amsterdam, Netherlands|Tergooi, Blaricum, Netherlands|Research Center Emmen, Emmen, Netherlands|Research Center Leeuwarden, Leeuwarden, Netherlands|Research Center Nijmegen, Nijmegen, Netherlands|Research Center Venlo, Venlo, Netherlands|Research Center Belchatow, Belchatow, Poland|Research Center Bielsko-Biala, Bielsko-Biala, Poland|Research center Chrzanow, Chrzanow, Poland|Research Center Tychy, Tychy, Poland|Research Center Zgierz, Zgierz, Poland | |
**Title:** Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis (NCT04128579)
**Summary:** This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
**Status:** COMPLETED
Study Phase: PHASE1
**Conditions:** Lupus Erythematosus|Lupus Nephritis
Intervention(s) Tested: DRUG: Itolizumab [Bmab 600]
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Incidence of Treatment Emergent Adverse Events, Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0., Type A up to Day 57 or Type B up to Day 253
The Secondary outcome measures of this study:
To characterize the PK of itolizumab, To characterize the pharmacokinetics of itolizumab, Type A up to Day 57 or Type B up to Day 253|CD6 receptor occupancy, the % levels of free versus EQ001-bound CD6 receptor on T cells, Type A up to Day 57 or Type B up to Day 253
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 55.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Equillium
**Study Collaborator(s):** Biocon Limited
**Study Dates:**
Start Date: 2019-10-01
Primary Completion Date: 2023-11-16
Completion Date: 2024-01-18
First Posted: 2019-10-16
**Study Location(s):**
AKDHC Medical Research Services, LLC, Sun City, Arizona, 85351, United States|California Institute of Renal Research, Chula Vista, California, 91910, United States|University of California San Diego Perlman Ambulatory Clinic, La Jolla, California, 92037, United States|Clinical Research of West Florida - Clearwater, Clearwater, Florida, 33765-2616, United States|Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Florida, 33309, United States|University of Florida, Division of Rheumatology, Gainesville, Florida, 32610, United States|Clinical Site Partners Leesburg, LLC, Leesburg, Florida, 34748, United States|SouthCoast Research Center Inc, Miami, Florida, 33136, United States|Hope Clinical Trials, Miami, Florida, 33165, United States|Omega Research Maitland, LLC, Orlando, Florida, 32810, United States|Clinical Research of West Florida - Tampa, Tampa, Florida, 33603, United States|University of South Florida, Tampa, Florida, 33606, United States|Georgia Nephrology, Lawrenceville, Georgia, 30046, United States|Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, 10461, United States|Northwell Health / Division of Rheumatology, Great Neck, New York, 11021, United States|Columbia University Medical Center, Div of Nephrology, New York, New York, 10032, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, 18017, United States|Dallas Renal Group, Dallas, Texas, 75230, United States|Prolato Clinical Research Center (PCRC), Houston, Texas, 77054, United States|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Medanta - The Medicity Hospital, Gurugramam, India|MAX Super Specialty Hospital, New Delhi, India|Jawaharlal Nehru Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India|Miedzyleski Szpital Specjalistyczny w Warszawie, Oddzial Nefrologiczny i Stacja Dializ, Warszawa, 04-749, Poland|SP ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Klinika Nefrologii, Hipertensjologii, Łódź, 92-213, Poland | |
**Title:** Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (NCT03793179)
**Summary:** This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
**Status:** ACTIVE_NOT_RECRUITING
Study Phase: PHASE3
**Conditions:** Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8
Intervention(s) Being Tested: PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Overall survival (OS), OS distributions will be estimated using the Kaplan-Meier method., From randomization to death from any cause, assessed up to 5 years post treatment
The Secondary outcome measures of this study:
Progression-free survival (PFS), PFS distributions will be estimated using the Kaplan-Meier method., From randomization to documented disease progression or death from any cause, assessed up to 5 years post treatment|Best objective response, Best objective response will be evaluated via Response Evaluation Criteria in Solid Tumors 1.1 criteria., Up to 5 years post treatment|Incidence of adverse events, Toxicities will be reported via the Common Terminology Criteria for Adverse Events criteria version 5.0. Toxicity rates between arms in the overall population will be compared using Fishers exact tests with a one-sided type I error rate of 1.25%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes., Up to 30 days post treatment|PD-L1 positivity, PD-L1 positivity will be defined as >= 1% Tumor Proportion Score (TPS) for the purpose of enrollment onto the trial. Strongly PD-L1 positive is defined as >= 50% TPS; weakly positive is defined as 1% - 49% TPS., At baseline
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 600.0
**Funder Type:** NIH
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** National Cancer Institute (NCI)
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-04-05
Primary Completion Date: 2028-12-31
Completion Date: 2028-12-31
First Posted: 2019-01-04
**Study Location(s):**
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, 36688, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, 98508, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, 99504, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, 99508, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, 99508, United States|Alaska Womens Cancer Care, Anchorage, Alaska, 99508, United States|Anchorage Oncology Centre, Anchorage, Alaska, 99508, United States|Katmai Oncology Group, Anchorage, Alaska, 99508, United States|Providence Alaska Medical Center, Anchorage, Alaska, 99508, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, 99701, United States|Kingman Regional Medical Center, Kingman, Arizona, 86401, United States|Cancer Center at Saint Josephs, Phoenix, Arizona, 85004, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, 85704, United States|Banner University Medical Center - Tucson, Tucson, Arizona, 85719, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, 85719, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, 72903, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, 71913, United States|NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, 72401, United States|CARTI Cancer Center, Little Rock, Arkansas, 72205, United States|Kaiser Permanente-Anaheim, Anaheim, California, 92806, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, 94531, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, 93420, United States|PCR Oncology, Arroyo Grande, California, 93420, United States|Sutter Auburn Faith Hospital, Auburn, California, 95602, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, 95603, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, 91706, United States|Kaiser Permanente-Bellflower, Bellflower, California, 90706, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, 94704, United States|Tower Cancer Research Foundation, Beverly Hills, California, 90211, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, 91505, United States|Mills-Peninsula Medical Center, Burlingame, California, 94010, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, 95682, United States|Mercy Cancer Center - Carmichael, Carmichael, California, 95608, United States|Mercy San Juan Medical Center, Carmichael, California, 95608, United States|Eden Hospital Medical Center, Castro Valley, California, 94546, United States|Sutter Davis Hospital, Davis, California, 95616, United States|Kaiser Permanente Dublin, Dublin, California, 94568, United States|21st Century Oncology - El Segundo, El Segundo, California, 90245, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, 95758, United States|Kaiser Permanente-Fontana, Fontana, California, 92335, United States|Kaiser Permanente-Fremont, Fremont, California, 94538, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, 94538, United States|Fresno Cancer Center, Fresno, California, 93720, United States|Kaiser Permanente-Fresno, Fresno, California, 93720, United States|Kaiser Permanente - Harbor City, Harbor City, California, 90710, United States|Kaiser Permanente-Irvine, Irvine, California, 92618, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, 90027, United States|Kaiser Permanente West Los Angeles, Los Angeles, California, 90034, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|Fremont - Rideout Cancer Center, Marysville, California, 95901, United States|Mercy Cancer Center, Merced, California, 95340, United States|Memorial Medical Center, Modesto, California, 95355, United States|Kaiser Permanente-Modesto, Modesto, California, 95356, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, 94040, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, 94040, United States|Sutter Cancer Research Consortium, Novato, California, 94945, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, 94611, United States|Kaiser Permanente-Oakland, Oakland, California, 94611, United States|Kaiser Permanente-Ontario, Ontario, California, 91761, United States|Saint Joseph Hospital - Orange, Orange, California, 92868, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, 94301, United States|VA Palo Alto Health Care System, Palo Alto, California, 94304, United States|Kaiser Permanente - Panorama City, Panorama City, California, 91402, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, 95670, United States|Kaiser Permanente- Marshall Medical Offices, Redwood City, California, 94063, United States|Kaiser Permanente-Redwood City, Redwood City, California, 94063, United States|Kaiser Permanente-Richmond, Richmond, California, 94801, United States|Kaiser Permanente-Riverside, Riverside, California, 92505, United States|Mercy Cancer Center - Rocklin, Rocklin, California, 95765, United States|Rohnert Park Cancer Center, Rohnert Park, California, 94928, United States|Kaiser Permanente-Roseville, Roseville, California, 95661, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, 95661, United States|Sutter Roseville Medical Center, Roseville, California, 95661, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, 95678, United States|Kaiser Permanente Downtown Commons, Sacramento, California, 95814, United States|Mercy Cancer Center - Sacramento, Sacramento, California, 95816, United States|Sutter Medical Center Sacramento, Sacramento, California, 95816, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Kaiser Permanente-South Sacramento, Sacramento, California, 95823, United States|South Sacramento Cancer Center, Sacramento, California, 95823, United States|Saint Helena Hospital, Saint Helena, California, 94574, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, 92103, United States|Kaiser Permanente-San Diego Mission, San Diego, California, 92108, United States|Kaiser Permanente-San Diego Zion, San Diego, California, 92120, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, 94115, United States|Kaiser Permanente-San Francisco, San Francisco, California, 94115, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, 95119, United States|Kaiser Permanente San Leandro, San Leandro, California, 94577, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, 93401, United States|Kaiser Permanente-San Marcos, San Marcos, California, 92078, United States|Kaiser San Rafael-Gallinas, San Rafael, California, 94903, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, 95051, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, 95065, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, 93444, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, 95403, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, 95403, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, 94080, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, 94080, United States|Kaiser Permanente-Stockton, Stockton, California, 95210, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, 94086, United States|Cedars-Sinai Cancer - Tarzana, Tarzana, California, 91356, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, 90505, United States|Torrance Memorial Medical Center, Torrance, California, 90509, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, 95687, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, 95688, United States|Kaiser Permanente-Vallejo, Vallejo, California, 94589, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, 94589, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, 94596, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, 91367, United States|Woodland Memorial Hospital, Woodland, California, 95695, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, 80012, United States|The Medical Center of Aurora, Aurora, Colorado, 80012, United States|UCHealth University of Colorado Hospital, Aurora, Colorado, 80045, United States|Boulder Community Hospital, Boulder, Colorado, 80301, United States|Boulder Community Foothills Hospital, Boulder, Colorado, 80303, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, 80304, United States|Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado, 80112, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, 80907, United States|Saint Francis Cancer Center, Colorado Springs, Colorado, 80923, United States|Cancer Center of Colorado at Sloans Lake, Denver, Colorado, 80204, United States|Kaiser Permanente-Franklin, Denver, Colorado, 80205, United States|National Jewish Health-Main Campus, Denver, Colorado, 80206, United States|The Womens Imaging Center, Denver, Colorado, 80209, United States|Porter Adventist Hospital, Denver, Colorado, 80210, United States|Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, 80218, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, 80220, United States|Rose Medical Center, Denver, Colorado, 80220, United States|Western Surgical Care, Denver, Colorado, 80220, United States|Mercy Medical Center, Durango, Colorado, 81301, United States|Southwest Oncology PC, Durango, Colorado, 81301, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, 80113, United States|Rocky Mountain Cancer Centers - Swedish, Englewood, Colorado, 80113, United States|Swedish Medical Center, Englewood, Colorado, 80113, United States|The Melanoma and Skin Cancer Institute, Englewood, Colorado, 80113, United States|Poudre Valley Hospital, Fort Collins, Colorado, 80524, United States|Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, 80528, United States|Mountain Blue Cancer Care Center, Golden, Colorado, 80401, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, 80401, United States|Saint Marys Hospital and Regional Medical Center, Grand Junction, Colorado, 81501, United States|Grand Valley Oncology, Grand Junction, Colorado, 81505, United States|Banner North Colorado Medical Center, Greeley, Colorado, 80631, United States|UCHealth Greeley Hospital, Greeley, Colorado, 80631, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, 80129, United States|Good Samaritan Medical Center, Lafayette, Colorado, 80026, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, 80026, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, 80228, United States|Saint Anthony Hospital, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, 80120, United States|Littleton Adventist Hospital, Littleton, Colorado, 80122, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, 80124, United States|Sky Ridge Medical Center, Lone Tree, Colorado, 80124, United States|Longmont United Hospital, Longmont, Colorado, 80501, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, 80501, United States|Medical Center of the Rockies, Loveland, Colorado, 80538, United States|Banner McKee Medical Center, Loveland, Colorado, 80539, United States|Parker Adventist Hospital, Parker, Colorado, 80138, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, 80138, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, 81004, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, 81008, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, 80260, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, 80260, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, 80033, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, 06418, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, 06824, United States|Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, 06437, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, 06105, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, 06510, United States|Yale University, New Haven, Connecticut, 06520, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, 06473, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, 06477, United States|Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, 06902, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, 06904, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, 06790, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, 06611, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, 06708, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, 06385, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, 06516, United States|Beebe South Coastal Health Campus, Frankford, Delaware, 19945, United States|Beebe Medical Center, Lewes, Delaware, 19958, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, 19713, United States|Helen F Graham Cancer Center, Newark, Delaware, 19713, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, 19713, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, 19718, United States|Beebe Health Campus, Rehoboth Beach, Delaware, 19971, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, 19973, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, 19801, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|George Washington University Medical Center, Washington, District of Columbia, 20037, United States|GenesisCare USA - Aventura FP, Aventura, Florida, 33180, United States|GenesisCare USA - Aventura, Aventura, Florida, 33180, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, 33180, United States|GenesisCare USA - Boca Raton FP02, Boca Raton, Florida, 33428, United States|GenesisCare USA - Boca Ration FP06, Boca Raton, Florida, 33431, United States|Holy Cross Hospital, Fort Lauderdale, Florida, 33308, United States|GenesisCare USA - Gladiolus, Fort Myers, Florida, 33908, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224-9980, United States|GenesisCare USA - Key West, Key West, Florida, 33040, United States|GenesisCare USA - Lakewood Ranch, Lakewood Ranch, Florida, 34202, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|GenesisCare USA - Palm Beach Gardens, Palm Beach Gardens, Florida, 33410, United States|Sacred Heart Hospital, Pensacola, Florida, 32504, United States|GenesisCare USA - Plantation, Plantation, Florida, 33324, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, 33607, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, 33612, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Good Samaritan Medical Center, West Palm Beach, Florida, 33401, United States|Cleveland Clinic-Weston, Weston, Florida, 33331, United States|University Cancer and Blood Center LLC, Athens, Georgia, 30607, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Emory Saint Josephs Hospital, Atlanta, Georgia, 30342, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Augusta Oncology Associates PC-DAntignac, Augusta, Georgia, 30901, United States|Augusta Oncology Associates PC-Wheeler, Augusta, Georgia, 30909, United States|Augusta University Medical Center, Augusta, Georgia, 30912, United States|Northeast Georgia Medical Center Braselton, Braselton, Georgia, 30517, United States|Atlanta VA Medical Center, Decatur, Georgia, 30033, United States|Northside Hospital - Duluth, Duluth, Georgia, 30096, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, 30501, United States|The Longstreet Clinic - Gainesville, Gainesville, Georgia, 30501, United States|Northside Hospital - Gwinnett, Lawrenceville, Georgia, 30046, United States|Lewis Cancer and Research Pavilion at Saint Josephs/Candler, Savannah, Georgia, 31405, United States|Summit Cancer Care-Candler, Savannah, Georgia, 31405, United States|Suburban Hematology Oncology Associates - Snellville, Snellville, Georgia, 30078, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, 31792, United States|South Georgia Medical Center/Pearlman Cancer Center, Valdosta, Georgia, 31602, United States|Hawaii Cancer Care - Westridge, Aiea, Hawaii, 96701, United States|Pali Momi Medical Center, Aiea, Hawaii, 96701, United States|Queens Cancer Center - Pearlridge, Aiea, Hawaii, 96701, United States|Straub Pearlridge Clinic, Aiea, Hawaii, 96701, United States|The Cancer Center of Hawaii-Pali Momi, Aiea, Hawaii, 96701, United States|The Queens Medical Center - West Oahu, Ewa Beach, Hawaii, 96706, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, 96813, United States|Island Urology, Honolulu, Hawaii, 96813, United States|Queens Cancer Cenrer - POB I, Honolulu, Hawaii, 96813, United States|Queens Medical Center, Honolulu, Hawaii, 96813, United States|Straub Clinic and Hospital, Honolulu, Hawaii, 96813, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, 96813, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, 96817, United States|Hawaii Diagnostic Radiology Services LLC, Honolulu, Hawaii, 96817, United States|Kuakini Medical Center, Honolulu, Hawaii, 96817, United States|Queens Cancer Center - Kuakini, Honolulu, Hawaii, 96817, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, 96817, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, 96819, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Straub Medical Center - Kahului Clinic, Kahului, Hawaii, 96732, United States|Castle Medical Center, Kailua, Hawaii, 96734, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, 96766, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, 83706, United States|Saint Lukes Cancer Institute - Boise, Boise, Idaho, 83712, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, 83605, United States|Kootenai Health - Coeur dAlene, Coeur dAlene, Idaho, 83814, United States|Walter Knox Memorial Hospital, Emmett, Idaho, 83617, United States|Saint Lukes Cancer Institute - Fruitland, Fruitland, Idaho, 83619, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, 83642, United States|Saint Lukes Cancer Institute - Meridian, Meridian, Idaho, 83642, United States|Saint Lukes Cancer Institute - Nampa, Nampa, Idaho, 83686, United States|Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, 83687, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, 83854, United States|Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, 83864, United States|Saint Lukes Cancer Institute - Twin Falls, Twin Falls, Idaho, 83301, United States|Saint Anthonys Health, Alton, Illinois, 62002, United States|Rush - Copley Medical Center, Aurora, Illinois, 60504, United States|Advocate Good Shepherd Hospital, Barrington, Illinois, 60010, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, 61704, United States|Loyola Center for Health at Burr Ridge, Burr Ridge, Illinois, 60527, United States|Illinois CancerCare-Canton, Canton, Illinois, 61520, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, 62902, United States|SIH Cancer Institute, Carterville, Illinois, 62918, United States|Illinois CancerCare-Carthage, Carthage, Illinois, 62321, United States|Centralia Oncology Clinic, Centralia, Illinois, 62801, United States|Saint Marys Hospital, Centralia, Illinois, 62801, United States|Northwestern University, Chicago, Illinois, 60611, United States|Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, 60612, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, 60612, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Swedish Covenant Hospital, Chicago, Illinois, 60625, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Advocate Illinois Masonic Medical Center, Chicago, Illinois, 60657, United States|AMG Crystal Lake - Oncology, Crystal Lake, Illinois, 60014, United States|Carle at The Riverfront, Danville, Illinois, 61832, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, 62526, United States|Decatur Memorial Hospital, Decatur, Illinois, 62526, United States|Illinois CancerCare-Dixon, Dixon, Illinois, 61021, United States|Advocate Good Samaritan Hospital, Downers Grove, Illinois, 60515, United States|Carle Physician Group-Effingham, Effingham, Illinois, 62401, United States|Crossroads Cancer Center, Effingham, Illinois, 62401, United States|Advocate Sherman Hospital, Elgin, Illinois, 60123, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, 60126, United States|Illinois CancerCare-Eureka, Eureka, Illinois, 61530, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, 60201, United States|Freeport Memorial Hospital/Leonard C Ferguson Cancer Center, Freeport, Illinois, 61032, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, 61401, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, 61401, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, 60026, United States|Advocate South Suburban Hospital, Hazel Crest, Illinois, 60429, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, 60035, United States|Edward Hines Jr VA Hospital, Hines, Illinois, 60141, United States|AMITA Health Cancer Institute and Outpatient Center, Hinsdale, Illinois, 60521, United States|Loyola Medicine Homer Glen, Homer Glen, Illinois, 60491, United States|Duly Health and Care Joliet, Joliet, Illinois, 60435, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, 61443, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, 60045, United States|AMG Libertyville - Oncology, Libertyville, Illinois, 60048, United States|Condell Memorial Hospital, Libertyville, Illinois, 60048, United States|Illinois CancerCare-Macomb, Macomb, Illinois, 61455, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, 61938, United States|Loyola University Medical Center, Maywood, Illinois, 60153, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, 60160, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, 62864, United States|Edward Hospital/Cancer Center, Naperville, Illinois, 60540, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, 60451, United States|Cancer Care Center of OFallon, OFallon, Illinois, 62269, United States|HSHS Saint Elizabeths Hospital, OFallon, Illinois, 62269, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, 60453-2699, United States|Northwestern Medicine Orland Park, Orland Park, Illinois, 60462, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, 60462, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, 61350, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, 60068, United States|Illinois CancerCare-Pekin, Pekin, Illinois, 61554, United States|Illinois CancerCare-Peoria, Peoria, Illinois, 61615, United States|Methodist Medical Center of Illinois, Peoria, Illinois, 61636, United States|Illinois CancerCare-Peru, Peru, Illinois, 61354, United States|Valley Radiation Oncology, Peru, Illinois, 61354, United States|Edward Hospital/Cancer Center?Plainfield, Plainfield, Illinois, 60585, United States|Illinois CancerCare-Princeton, Princeton, Illinois, 61356, United States|UW Health Carbone Cancer Center Rockford, Rockford, Illinois, 61114, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Springfield Clinic, Springfield, Illinois, 62702, United States|Memorial Medical Center, Springfield, Illinois, 62781, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, 62226, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|The Carle Foundation Hospital, Urbana, Illinois, 61801, United States|Illinois CancerCare - Washington, Washington, Illinois, 61571, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, 60560, United States|Reid Health, Richmond, Indiana, 47374, United States|Mary Greeley Medical Center, Ames, Iowa, 50010, United States|McFarland Clinic - Ames, Ames, Iowa, 50010, United States|Mission Cancer and Blood - Ankeny, Ankeny, Iowa, 50023, United States|University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf, Iowa, 52722, United States|McFarland Clinic - Boone, Boone, Iowa, 50036, United States|Saint Anthony Regional Hospital, Carroll, Iowa, 51401, United States|Mercy Hospital, Cedar Rapids, Iowa, 52403, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, 52403, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, 50325, United States|Mission Cancer and Blood - West Des Moines, Clive, Iowa, 50325, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, 51503, United States|Heartland Oncology and Hematology LLP, Council Bluffs, Iowa, 51503, United States|Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa, 51503, United States|Greater Regional Medical Center, Creston, Iowa, 50801, United States|Iowa Methodist Medical Center, Des Moines, Iowa, 50309, United States|Mission Cancer and Blood - Des Moines, Des Moines, Iowa, 50309, United States|Broadlawns Medical Center, Des Moines, Iowa, 50314, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, 50314, United States|Mission Cancer and Blood - Laurel, Des Moines, Iowa, 50314, United States|Iowa Lutheran Hospital, Des Moines, Iowa, 50316, United States|McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, 50501, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, 50501, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|McFarland Clinic - Jefferson, Jefferson, Iowa, 50129, United States|McFarland Clinic - Marshalltown, Marshalltown, Iowa, 50158, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, 51101, United States|MercyOne Waterloo Cancer Center, Waterloo, Iowa, 50702, United States|Methodist West Hospital, West Des Moines, Iowa, 50266-7700, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, 50266, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, 66720, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, 67337, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, 67801, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, 67042, United States|University of Kansas Clinical Research Center, Fairway, Kansas, 66205, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, 67846, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, 67530, United States|HaysMed, Hays, Kansas, 67601, United States|Cancer Center of Kansas-Independence, Independence, Kansas, 67301, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, 66112, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, 67068, United States|Lawrence Memorial Hospital, Lawrence, Kansas, 66044, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, 67905, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, 66502, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, 67460, United States|Cancer Center of Kansas - Newton, Newton, Kansas, 67114, United States|Olathe Health Cancer Center, Olathe, Kansas, 66061, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, 66210, United States|Saint Lukes South Hospital, Overland Park, Kansas, 66213, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, 67357, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, 66762, United States|Freeman Physician Group of Pittsburg, Pittsburg, Kansas, 66762, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, 67124, United States|Cancer Center of Kansas - Salina, Salina, Kansas, 67401, United States|Salina Regional Health Center, Salina, Kansas, 67401, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, 66606, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, 67152, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, 66205, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, 67208, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, 67214, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, 67214, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, 67156, United States|Flaget Memorial Hospital, Bardstown, Kentucky, 40004, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, 40701, United States|Saint Joseph Hospital, Lexington, Kentucky, 40504, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, 40504, United States|Saint Joseph Hospital East, Lexington, Kentucky, 40509, United States|Saint Joseph London, London, Kentucky, 40741, United States|Jewish Hospital, Louisville, Kentucky, 40202, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, 40215, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, 40245, United States|Saint Joseph Mount Sterling, Mount Sterling, Kentucky, 40353, United States|Mercy Health - Paducah Medical Oncology and Hematology, Paducah, Kentucky, 42003, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, 40165, United States|West Jefferson Medical Center, Marrero, Louisiana, 70072, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, 71202, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, 70112, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70112, United States|Veterans Administration Medical Center - New Orleans, New Orleans, Louisiana, 70112, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, 71103, United States|Eastern Maine Medical Center, Bangor, Maine, 04401, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, 04412, United States|Greater Baltimore Medical Center, Baltimore, Maryland, 21204, United States|MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, 21237, United States|MedStar Good Samaritan Hospital, Baltimore, Maryland, 21239, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, 21601, United States|Christiana Care - Union Hospital, Elkton, Maryland, 21921, United States|Beverly Hospital, Beverly, Massachusetts, 01915, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, 01805, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, 01930, United States|Lowell General Hospital, Lowell, Massachusetts, 01854, United States|Lahey Medical Center-Peabody, Peabody, Massachusetts, 01960, United States|Mercy Medical Center, Springfield, Massachusetts, 01104, United States|Baystate Medical Center, Springfield, Massachusetts, 01199, United States|Winchester Hospital, Winchester, Massachusetts, 01890, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, 01655, United States|Hickman Cancer Center, Adrian, Michigan, 49221, United States|Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan, 48106, United States|Bronson Battle Creek, Battle Creek, Michigan, 49017, United States|Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan, 48114, United States|Trinity Health Medical Center - Brighton, Brighton, Michigan, 48114, United States|Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan, 48188, United States|Trinity Health Medical Center - Canton, Canton, Michigan, 48188, United States|Caro Cancer Center, Caro, Michigan, 48723, United States|Chelsea Hospital, Chelsea, Michigan, 48118, United States|Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, 48118, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, 48346, United States|Michigan Healthcare Professionals Clarkston, Clarkston, Michigan, 48346, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, 48346, United States|Ascension Saint John Hospital, Detroit, Michigan, 48236, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, 48054, United States|OSF Saint Francis Hospital and Medical Group, Escanaba, Michigan, 49829, United States|Michigan Healthcare Professionals Farmington, Farmington Hills, Michigan, 48334, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, 48503, United States|Genesee Hematology Oncology PC, Flint, Michigan, 48503, United States|Genesys Hurley Cancer Institute, Flint, Michigan, 48503, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, 49503, United States|Corewell Health Grand Rapids Hospitals - Helen DeVos Childrens Hospital, Grand Rapids, Michigan, 49503, United States|Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan, 49503, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, 48236, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, 48236, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, 48236, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007, United States|Ascension Borgess Cancer Center, Kalamazoo, Michigan, 49009, United States|Borgess Medical Center, Kalamazoo, Michigan, 49048, United States|University of Michigan Health - Sparrow Lansing, Lansing, Michigan, 48912, United States|Hope Cancer Clinic, Livonia, Michigan, 48154, United States|Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan, 48154, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, 48044, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, 48044, United States|Michigan Healthcare Professionals Macomb, Macomb, Michigan, 48044, United States|Michigan Healthcare Professionals Madison Heights, Madison Heights, Michigan, 48071, United States|Saint Marys Oncology/Hematology Associates of Marlette, Marlette, Michigan, 48453, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, 48162, United States|Trinity Health Muskegon Hospital, Muskegon, Michigan, 49444, United States|Corewell Health Lakeland Hospitals - Niles Hospital, Niles, Michigan, 49120, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, 49444, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, 48374, United States|Hope Cancer Center, Pontiac, Michigan, 48341, United States|Michigan Healthcare Professionals Pontiac, Pontiac, Michigan, 48341, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, 48341, United States|Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, 48341, United States|Huron Medical Center PC, Port Huron, Michigan, 48060, United States|Lake Huron Medical Center, Port Huron, Michigan, 48060, United States|Corewell Health Reed City Hospital, Reed City, Michigan, 49677, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, 48309, United States|Ascension Saint Marys Hospital, Saginaw, Michigan, 48601, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, 48604, United States|Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center, Saint Joseph, Michigan, 49085, United States|Corewell Health Lakeland Hospitals - Saint Joseph Hospital, Saint Joseph, Michigan, 49085, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, 48075, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, 48312, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, 48764, United States|Munson Medical Center, Traverse City, Michigan, 49684, United States|Michigan Healthcare Professionals Troy, Troy, Michigan, 48098, United States|Advanced Breast Care Center PLLC, Warren, Michigan, 48088, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, 48093, United States|Macomb Hematology Oncology PC, Warren, Michigan, 48093, United States|Michigan Breast Specialists-Warren, Warren, Michigan, 48093, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, 48093, United States|Saint Marys Oncology/Hematology Associates of West Branch, West Branch, Michigan, 48661, United States|University of Michigan Health - West, Wyoming, Michigan, 49519, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, 48106, United States|Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, 48197, United States|Riverwood Healthcare Center, Aitkin, Minnesota, 56431, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, 56007, United States|Essentia Health - Baxter Clinic, Baxter, Minnesota, 56425, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, 56601, United States|Essentia Health Saint Josephs Medical Center, Brainerd, Minnesota, 56401, United States|Fairview Ridges Hospital, Burnsville, Minnesota, 55337, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, 55337, United States|Cambridge Medical Center, Cambridge, Minnesota, 55008, United States|Mercy Hospital, Coon Rapids, Minnesota, 55433, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, 56636, United States|Essentia Health Saint Marys - Detroit Lakes Clinic, Detroit Lakes, Minnesota, 56501, United States|Essentia Health Cancer Center, Duluth, Minnesota, 55805, United States|Essentia Health Saint Marys Medical Center, Duluth, Minnesota, 55805, United States|Miller-Dwan Hospital, Duluth, Minnesota, 55805, United States|Fairview Southdale Hospital, Edina, Minnesota, 55435, United States|Essentia Health - Ely Clinic, Ely, Minnesota, 55731, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, 56537, United States|Essentia Health - Fosston, Fosston, Minnesota, 56542, United States|Unity Hospital, Fridley, Minnesota, 55432, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, 55746, United States|Essentia Health - International Falls Clinic, International Falls, Minnesota, 56649, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, 56001, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, 55369, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, 55109, United States|Saint Johns Hospital - Healtheast, Maplewood, Minnesota, 55109, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|Minneapolis VA Medical Center, Minneapolis, Minnesota, 55417, United States|Health Partners Inc, Minneapolis, Minnesota, 55454, United States|Monticello Cancer Center, Monticello, Minnesota, 55362, United States|Essentia Health - Moose Lake Clinic, Moose Lake, Minnesota, 55767, United States|New Ulm Medical Center, New Ulm, Minnesota, 56073, United States|Essentia Health - Park Rapids, Park Rapids, Minnesota, 56470, United States|Fairview Northland Medical Center, Princeton, Minnesota, 55371, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, 55422, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, 55416, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|United Hospital, Saint Paul, Minnesota, 55102, United States|Essentia Health Sandstone, Sandstone, Minnesota, 55072, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, 55379, United States|Lakeview Hospital, Stillwater, Minnesota, 55082, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, 56701, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, 55792, United States|Ridgeview Medical Center, Waconia, Minnesota, 55387, United States|Rice Memorial Hospital, Willmar, Minnesota, 56201, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, 55125, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, 56187, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, 55092, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, 39705, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, 38901, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, 38652, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, 38655, United States|Singing River Hospital, Pascagoula, Mississippi, 39581, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, 38671, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, 63011, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, 65613, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, 63628, United States|Cox Cancer Center Branson, Branson, Missouri, 65616, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, 63703, United States|Southeast Cancer Center, Cape Girardeau, Missouri, 63703, United States|Saint Lukes Hospital, Chesterfield, Missouri, 63017, United States|Parkland Health Center - Farmington, Farmington, Missouri, 63640, United States|MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri, 65109, United States|Freeman Health System, Joplin, Missouri, 64804, United States|Mercy Hospital Joplin, Joplin, Missouri, 64804, United States|University Health Truman Medical Center, Kansas City, Missouri, 64108, United States|Saint Lukes Hospital of Kansas City, Kansas City, Missouri, 64111, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, 64131, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, 64154, United States|University of Kansas Cancer Center - Lees Summit, Lees Summit, Missouri, 64064, United States|Saint Lukes East - Lees Summit, Lees Summit, Missouri, 64086, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, 64116, United States|Lake Regional Hospital, Osage Beach, Missouri, 65065, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, 65401, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, 65401, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, 64506, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, 63109, United States|Mercy Hospital South, Saint Louis, Missouri, 63128, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, 63141, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, 63670, United States|Mercy Hospital Springfield, Springfield, Missouri, 65804, United States|CoxHealth South Hospital, Springfield, Missouri, 65807, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, 63080, United States|BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri, 63127, United States|Mercy Hospital Washington, Washington, Missouri, 63090, United States|Community Hospital of Anaconda, Anaconda, Montana, 59711, United States|Billings Clinic Cancer Center, Billings, Montana, 59101, United States|Saint Vincent Healthcare, Billings, Montana, 59101, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, 59715, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, 59701, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, 59405, United States|Great Falls Clinic, Great Falls, Montana, 59405, United States|Saint Peters Community Hospital, Helena, Montana, 59601, United States|Kalispell Regional Medical Center, Kalispell, Montana, 59901, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, 59802, United States|Community Medical Center, Missoula, Montana, 59804, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, 68123, United States|Nebraska Cancer Specialists/Oncology Hematology West PC, Grand Island, Nebraska, 68803, United States|Heartland Hematology and Oncology, Kearney, Nebraska, 68845, United States|CHI Health Good Samaritan, Kearney, Nebraska, 68847, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, 68510, United States|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha, Nebraska, 68114, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Oncology Associates PC, Omaha, Nebraska, 68114, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, 68118, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, 68122, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, 68122, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, 68124, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, 68130, United States|Creighton University Medical Center, Omaha, Nebraska, 68131, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Midlands Community Hospital, Papillion, Nebraska, 68046, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, 89703, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, 89052, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, 89052, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, 89074, United States|GenesisCare USA - Henderson, Henderson, Nevada, 89074, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, 89074, United States|Las Vegas Urology - Pebble, Henderson, Nevada, 89074, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, 89074, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, 89074, United States|Desert West Surgery, Las Vegas, Nevada, 89102, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, 89102, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, 89103, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, 89106, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, 89106, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, 89106, United States|GenesisCare USA - Las Vegas, Las Vegas, Nevada, 89109, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, 89109, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, 89113, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, 89113, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, 89113, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, 89113, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, 89119, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, 89128, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, 89128, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, 89128, United States|GenesisCare USA - Vegas Tenaya, Las Vegas, Nevada, 89128, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, 89128, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, 89128, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, 89128, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, 89128, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, 89128, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, 89144, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, 89144, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, 89144, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, 89148-2405, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|GenesisCare USA - Fort Apache, Las Vegas, Nevada, 89148, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, 89148, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, 89149, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, 89169, United States|University Cancer Center, Las Vegas, Nevada, 89169, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, 89048, United States|Renown Regional Medical Center, Reno, Nevada, 89502, United States|Saint Marys Regional Medical Center, Reno, Nevada, 89503, United States|Radiation Oncology Associates, Reno, Nevada, 89509, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, 03301, United States|Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, 03756, United States|Elliot Hospital, Manchester, New Hampshire, 03103, United States|Solinsky Center for Cancer Care, Manchester, New Hampshire, 03103, United States|Virtua Samson Cancer Center, Moorestown, New Jersey, 08057, United States|Morristown Medical Center, Morristown, New Jersey, 07960, United States|Inspira Medical Center Mullica Hill, Mullica Hill, New Jersey, 08062, United States|Overlook Hospital, Summit, New Jersey, 07902, United States|Virtua Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87106, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, 13021, United States|Lourdes Hospital, Binghamton, New York, 13905, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, 10461, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, 10467, United States|James J Peters VA Medical Center, Bronx, New York, 10468, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, 13057, United States|Glens Falls Hospital, Glens Falls, New York, 12801, United States|Mount Sinai Chelsea, New York, New York, 10011, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|Mount Sinai West, New York, New York, 10019, United States|Mount Sinai Hospital, New York, New York, 10029, United States|Upstate Cancer Center at Oswego, Oswego, New York, 13126, United States|University of Rochester, Rochester, New York, 14642, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|State University of New York Upstate Medical University, Syracuse, New York, 13210, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, 13215, United States|SUNY Upstate Medical Center-Community Campus, Syracuse, New York, 13215, United States|Upstate Cancer Center at Verona, Verona, New York, 13478, United States|Wilmot Cancer Institute at Webster, Webster, New York, 14580, United States|Atrium Health Stanly/LCI-Albemarle, Albemarle, North Carolina, 28002, United States|Mission Hospital, Asheville, North Carolina, 28801, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, 28803, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27599, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Atrium Health Pineville/LCI-Pineville, Charlotte, North Carolina, 28210, United States|Levine Cancer Institute-SouthPark, Charlotte, North Carolina, 28211, United States|Atrium Health University City/LCI-University, Charlotte, North Carolina, 28262, United States|Levine Cancer Institute-Ballantyne, Charlotte, North Carolina, 28277, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, 28328, United States|AdventHealth Infusion Center Haywood, Clyde, North Carolina, 28721, United States|Atrium Health Cabarrus/LCI-Concord, Concord, North Carolina, 28025, United States|Durham VA Medical Center, Durham, North Carolina, 27705, United States|Levine Cancer Institute - Rutherford, Forest City, North Carolina, 28043, United States|Levine Cancer Institute-Gaston, Gastonia, North Carolina, 28054, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, 27534, United States|East Carolina University, Greenville, North Carolina, 27834, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, 28791, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, 28792, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, 28546, United States|ECU Health Oncology Kenansville, Kenansville, North Carolina, 28349, United States|ECU Health Oncology Kinston, Kinston, North Carolina, 28501, United States|Atrium Health Lincoln/LCI-Lincolnton, Lincolnton, North Carolina, 28092, United States|Levine Cancer Institute - Union West, Matthews, North Carolina, 28104, United States|Atrium Health Union/LCI-Union, Monroe, North Carolina, 28112, United States|ECU Health Oncology Richlands, Richlands, North Carolina, 28574, United States|WG Hefner VA Medical Center, Salisbury, North Carolina, 28144, United States|Atrium Health Cleveland/LCI-Cleveland, Shelby, North Carolina, 28150, United States|AdventHealth Infusion Center Weaverville, Weaverville, North Carolina, 28787, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, 58501, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, 58103, United States|Sanford South University Medical Center, Fargo, North Dakota, 58103, United States|Southpointe-Sanford Medical Center Fargo, Fargo, North Dakota, 58103, United States|Sanford Medical Center Fargo, Fargo, North Dakota, 58104, United States|Sanford Broadway Medical Center, Fargo, North Dakota, 58122, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, 58122, United States|Essentia Health - Jamestown Clinic, Jamestown, North Dakota, 58401, United States|UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio, 44011, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, 44122, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, 45431, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, 45714, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, 44512, United States|Cleveland Clinic Mercy Hospital, Canton, Ohio, 44708, United States|Mercy Hematology and Oncology Associates Inc, Canton, Ohio, 44708, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, 45459, United States|Miami Valley Hospital South, Centerville, Ohio, 45459, United States|Geauga Hospital, Chardon, Ohio, 44024, United States|Adena Regional Medical Center, Chillicothe, Ohio, 45601, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, 45219, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, 45220, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, 45236, United States|Bethesda North Hospital, Cincinnati, Ohio, 45242, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, 45247, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, 45255, United States|Case Western Reserve University, Cleveland, Ohio, 44106, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, 44111, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Mount Carmel East Hospital, Columbus, Ohio, 43213, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, 43214, United States|Riverside Methodist Hospital, Columbus, Ohio, 43214, United States|Grant Medical Center, Columbus, Ohio, 43215, United States|The Mark H Zangmeister Center, Columbus, Ohio, 43219, United States|Mount Carmel Health Center West, Columbus, Ohio, 43222, United States|Doctors Hospital, Columbus, Ohio, 43228, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, 45406, United States|Miami Valley Hospital, Dayton, Ohio, 45409, United States|Premier Blood and Cancer Center, Dayton, Ohio, 45409, United States|Dayton Physician LLC - Englewood, Dayton, Ohio, 45415, United States|Miami Valley Hospital North, Dayton, Ohio, 45415, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, 43015, United States|Grady Memorial Hospital, Delaware, Ohio, 43015, United States|Columbus Oncology and Hematology Associates, Dublin, Ohio, 43016, United States|Dublin Methodist Hospital, Dublin, Ohio, 43016, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, 44035, United States|Armes Family Cancer Center, Findlay, Ohio, 45840, United States|Blanchard Valley Hospital, Findlay, Ohio, 45840, United States|Orion Cancer Care, Findlay, Ohio, 45840, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, 45005-1066, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, 45005, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, 43230, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, 45331, United States|Miami Valley Cancer Care and Infusion, Greenville, Ohio, 45331, United States|Wayne Hospital, Greenville, Ohio, 45331, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, 43123, United States|Zangmeister Center Grove City, Grove City, Ohio, 43123, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, 44131, United States|Greater Dayton Cancer Center, Kettering, Ohio, 45409, United States|First Dayton Cancer Care, Kettering, Ohio, 45420, United States|Kettering Medical Center, Kettering, Ohio, 45429, United States|Fairfield Medical Center, Lancaster, Ohio, 43130, United States|Saint Ritas Medical Center, Lima, Ohio, 45801, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, 44903, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, 44906, United States|Marietta Memorial Hospital, Marietta, Ohio, 45750, United States|OhioHealth Marion General Hospital, Marion, Ohio, 43302, United States|Memorial Hospital, Marysville, Ohio, 43040, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, 43537, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, 44124, United States|UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio, 44124, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, 44060, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, 44130, United States|Knox Community Hospital, Mount Vernon, Ohio, 43050, United States|Mount Carmel New Albany Surgical Hospital, New Albany, Ohio, 43054, United States|Licking Memorial Hospital, Newark, Ohio, 43055, United States|Newark Radiation Oncology, Newark, Ohio, 43055, United States|University Hospitals Parma Medical Center, Parma, Ohio, 44129, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, 43551, United States|Southern Ohio Medical Center, Portsmouth, Ohio, 45662, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, 44266, United States|North Coast Cancer Care, Sandusky, Ohio, 44870, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, 44870, United States|Springfield Regional Cancer Center, Springfield, Ohio, 45504, United States|Springfield Regional Medical Center, Springfield, Ohio, 45504, United States|Trinitys Tony Teramana Cancer Center, Steubenville, Ohio, 43952, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, 44136, United States|Mercy Health - Saint Vincent Hospital, Toledo, Ohio, 43608, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, 43623, United States|Mercy Health Sylvania Radiation Oncology Center, Toledo, Ohio, 43623, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, 43623, United States|Dayton Physicians LLC - Troy, Troy, Ohio, 45373, United States|Upper Valley Medical Center, Troy, Ohio, 45373, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, 44281, United States|South Pointe Hospital, Warrensville Heights, Ohio, 44122, United States|Saint Joseph Warren Hospital, Warren, Ohio, 44484, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, 45069, United States|Saint Anns Hospital, Westerville, Ohio, 43081, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, 44145, United States|UHHS-Westlake Medical Center, Westlake, Ohio, 44145, United States|Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio, 45177, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, 44691, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, 45433, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, 44501, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, 43701, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, 73120, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, 74146, United States|Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon, 97814, United States|Saint Charles Health System, Bend, Oregon, 97701, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, 97015, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, 97015, United States|Bay Area Hospital, Coos Bay, Oregon, 97420, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon, 97914, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, 97045, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence Saint Vincent Medical Center, Portland, Oregon, 97225, United States|Saint Charles Health System-Redmond, Redmond, Oregon, 97756, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, 18103, United States|UPMC Altoona, Altoona, Pennsylvania, 16601, United States|UPMC Cancer Center-Bethel Park, Bethel Park, Pennsylvania, 15102, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, 18017, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, 19010, United States|UPMC Camp Hill, Camp Hill, Pennsylvania, 17011, United States|Carlisle Regional Cancer Center, Carlisle, Pennsylvania, 17015, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, 19317, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, 17201, United States|WellSpan Medical Oncology and Hematology, Chambersburg, Pennsylvania, 17201, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, 18301, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, 17522, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, 17522, United States|UPMC Hillman Cancer Center Erie, Erie, Pennsylvania, 16505, United States|Adams Cancer Center, Gettysburg, Pennsylvania, 17325, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, 15601, United States|WellSpan Medical Oncology and Hematology, Hanover, Pennsylvania, 17331, United States|UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania, 17101, United States|UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg, Pennsylvania, 17109, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, 18201, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, 17042, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, 15132, United States|UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg, Pennsylvania, 17050, United States|Riddle Memorial Hospital, Media, Pennsylvania, 19063, United States|Arnold Palmer Cancer Center Medical Oncology Norwin, N. Huntingdon, Pennsylvania, 15642, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, 19301, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, 19104, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Temple University Hospital, Philadelphia, Pennsylvania, 19140, United States|Oncology Hematology Association, Pittsburgh, Pennsylvania, 15215, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, 15215, United States|UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, 15219, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, 15237, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, 15243, United States|Pottstown Hospital, Pottstown, Pennsylvania, 19464, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, 16346, United States|UPMC Cancer Center-Washington, Washington, Pennsylvania, 15301, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, 19096, United States|Cancer Care Associates of York, York, Pennsylvania, 17403, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, 17403, United States|WellSpan Health-York Hospital, York, Pennsylvania, 17403, United States|UPMC Memorial, York, Pennsylvania, 17408, United States|Kent Hospital, Warwick, Rhode Island, 02886, United States|Smilow Cancer Hospital Care Center - Westerly, Westerly, Rhode Island, 02891, United States|Saint Josephs/Candler - Bluffton Campus, Bluffton, South Carolina, 29910, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, 29316, United States|Ralph H Johnson VA Medical Center, Charleston, South Carolina, 29401, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Prisma Health Richland Hospital, Columbia, South Carolina, 29203, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, 29341, United States|Tidelands Georgetown Memorial Hospital, Georgetown, South Carolina, 29440, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, 29605, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, 29605, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, 29605, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, 29615, United States|Self Regional Healthcare, Greenwood, South Carolina, 29646, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, 29650, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, 29651, United States|South Carolina Cancer Specialists PC, Hilton Head Island, South Carolina, 29926-3827, United States|Carolina Regional Cancer Center, Myrtle Beach, South Carolina, 29577, United States|Levine Cancer Institute-Rock Hill, Rock Hill, South Carolina, 29732, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, 29672, United States|North Grove Medical Park, Spartanburg, South Carolina, 29303, United States|Spartanburg Medical Center, Spartanburg, South Carolina, 29303, United States|Spartanburg Medical Center - Mary Black Campus, Spartanburg, South Carolina, 29307, United States|MGC Hematology Oncology-Union, Union, South Carolina, 29379, United States|Rapid City Regional Hospital, Rapid City, South Dakota, 57701, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, 57104, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States|University Cancer Specialists - Alcoa, Alcoa, Tennessee, 37701, United States|Bristol Regional Medical Center, Bristol, Tennessee, 37620, United States|Memorial Hospital, Chattanooga, Tennessee, 37404, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, 38017, United States|Vanderbilt-Ingram Cancer Center at Franklin, Franklin, Tennessee, 37067, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, 37067, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, 37343, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, 37660, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, 37660, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, 37920, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, 38120, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Memorial GYN Plus, Ooltewah, Tennessee, 37363, United States|Houston Methodist San Jacinto Hospital, Baytown, Texas, 77521, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, 77802, United States|Dallas VA Medical Center, Dallas, Texas, 75216, United States|Parkland Memorial Hospital, Dallas, Texas, 75235, United States|UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas, 75237, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Tarrant County Hospital District/JPS Health Network, Fort Worth, Texas, 76104, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, 76104, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Methodist Willowbrook Hospital, Houston, Texas, 77070, United States|Houston Methodist West Hospital, Houston, Texas, 77094, United States|Houston Methodist Saint John Hospital, Nassau Bay, Texas, 77058, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, 75080, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, 77479, United States|Houston Methodist The Woodlands Hospital, The Woodlands, Texas, 77385, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, 84003, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, 84720, United States|Logan Regional Hospital, Logan, Utah, 84321, United States|Intermountain Medical Center, Murray, Utah, 84107, United States|McKay-Dee Hospital Center, Ogden, Utah, 84403, United States|Utah Valley Regional Medical Center, Provo, Utah, 84604, United States|Riverton Hospital, Riverton, Utah, 84065, United States|Saint George Regional Medical Center, Saint George, Utah, 84770, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, 84106, United States|LDS Hospital, Salt Lake City, Utah, 84143, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, 05602, United States|University of Vermont Medical Center, Burlington, Vermont, 05401, United States|University of Vermont and State Agricultural College, Burlington, Vermont, 05405, United States|Dartmouth Cancer Center - North, Saint Johnsbury, Vermont, 05819, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, 24201, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States|Augusta Health Center for Cancer and Blood Disorders, Fishersville, Virginia, 22939, United States|Southwest VA Regional Cancer Center, Norton, Virginia, 24273, United States|Virginia Cancer Institute, Richmond, Virginia, 23229, United States|VCU Massey Cancer Center at Stony Point, Richmond, Virginia, 23235, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298, United States|VCU Community Memorial Health Center, South Hill, Virginia, 23970, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, 98520, United States|MultiCare Auburn Medical Center, Auburn, Washington, 98001, United States|Overlake Medical Center, Bellevue, Washington, 98004, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, 98225, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, 98310, United States|Highline Medical Center-Main Campus, Burien, Washington, 98166, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, 98531, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, 98026, United States|Saint Elizabeth Hospital, Enumclaw, Washington, 98022, United States|Providence Regional Cancer Partnership, Everett, Washington, 98201, United States|Saint Francis Hospital, Federal Way, Washington, 98003, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, 98335, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, 98029, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, 98503, United States|Saint Clare Hospital, Lakewood, Washington, 98499, United States|PeaceHealth Saint John Medical Center, Longview, Washington, 98632, United States|Jefferson Healthcare, Port Townsend, Washington, 98368, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, 98370, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, 98372, United States|Valley Medical Center, Renton, Washington, 98055, United States|Pacific Gynecology Specialists, Seattle, Washington, 98104, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, 98107, United States|Kaiser Permanente Washington, Seattle, Washington, 98112, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, 98122-5711, United States|Swedish Medical Center-First Hill, Seattle, Washington, 98122, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, 98284, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, 98584, United States|Saint Michael Cancer Center, Silverdale, Washington, 98383, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, 99216, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington, 99204, United States|MultiCare Deaconess Cancer and Blood Specialty Center - North, Spokane, Washington, 99218, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, 98405, United States|Mary Bridge Childrens Hospital and Health Center, Tacoma, Washington, 98405, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, 98405, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, 98405, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, 98664, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, 99362, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, 98902, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, 98597, United States|West Virginia University Charleston Division, Charleston, West Virginia, 25304, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, 25701, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, 54409, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, 54915, United States|Duluth Clinic Ashland, Ashland, Wisconsin, 54806, United States|Northwest Wisconsin Cancer Center, Ashland, Wisconsin, 54806, United States|SSM Health Dean Medical Group - Baraboo, Baraboo, Wisconsin, 53913, United States|Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin, 53045, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, 53105, United States|Ascension Calumet Hospital, Chilton, Wisconsin, 53014, United States|Aurora Saint Lukes South Shore, Cudahy, Wisconsin, 53110, United States|HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, 54701, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, 54701, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, 54701, United States|Mayo Clinic Health System Eau Claire Hospital-Luther Campus, Eau Claire, Wisconsin, 54703, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, 54937, United States|Ascension Saint Francis - Reiman Cancer Center, Franklin, Wisconsin, 53132, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, 53022, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, 53024, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, 54301, United States|Saint Vincent Hospital Cancer Center at Saint Marys, Green Bay, Wisconsin, 54303, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, 54311, United States|Essentia Health-Hayward Clinic, Hayward, Wisconsin, 54843, United States|SSM Health Dean Medical Group - Janesville, Janesville, Wisconsin, 53546, United States|Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, 53548, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, 53142, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, 54601, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, 54601, United States|SSM Health Dean Medical Group - South Madison Campus, Madison, Wisconsin, 53715, United States|University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, 53792, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, 54221, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, 54143, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, 54143, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, 54449, United States|Aspirus Medford Hospital, Medford, Wisconsin, 54451, United States|Ascension Columbia Saint Marys Hospital Ozaukee, Mequon, Wisconsin, 53097, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, 53209, United States|Ascension Columbia Saint Marys Hospital - Milwaukee, Milwaukee, Wisconsin, 53211, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, 53215, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, 53233, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, 54548, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, 53149, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, 54017, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, 53066, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, 54154, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, 54904, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, 54904, United States|Ascension All Saints Hospital, Racine, Wisconsin, 53405, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, 53406, United States|Ascension Saint Marys Hospital, Rhinelander, Wisconsin, 54501, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, 54868, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, 53081, United States|Saint Vincent Hospital Cancer Center at Sheboygan, Sheboygan, Wisconsin, 53081, United States|Sheboygan Phyisicans Group, Sheboygan, Wisconsin, 53081, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, 53081, United States|Essentia Health-Spooner Clinic, Spooner, Wisconsin, 54801, United States|Ascension Saint Michaels Hospital, Stevens Point, Wisconsin, 54481, United States|Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, 54482, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, 54235-1495, United States|Aurora Medical Center in Summit, Summit, Wisconsin, 53066, United States|Essentia Health Saint Marys Hospital - Superior, Superior, Wisconsin, 54880, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, 54241, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, 53188, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, 53188, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, 54401, United States|Ascension Medical Group Southeast Wisconsin - Mayfair Road, Wauwatosa, Wisconsin, 53226, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, 53226, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, 53227, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, 54476, United States|Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BCCA-Fraser Valley Cancer Centre, Surrey, British Columbia, V3V 1Z2, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada|Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada|Niagara Health System-Saint Catharines General, Saint Catharines, Ontario, L2S 0A9, Canada|Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, P7B 6V4, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|PEI Cancer Treatment Centre-Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, C1A 8T5, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, H3H 2R9, Canada|CHA Hopital LEnfant-Jesus, Quebec City, Quebec, G1J 1Z4, Canada|FHP Health Center-Guam, Tamuning, 96913, Guam | |
**Title:** Safety and Performance Study of the Nyxoah SAT System for Treating OSA (NCT02312479)
**Summary:** A prospective open-label, single treatment study to assess the safety and the performance of the Nyxoah SAT system for the treatment of Obstructive Sleep Apnea
**Status:** TERMINATED
Study Phase: N/A
**Conditions:** Obstructive Sleep Apnea
Intervention(s) Tested: DEVICE: Nyxoah SAT system
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Incidence of serious device related adverse events, 6-months post-implantation|Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation, 6-months post-implantation
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 6.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Nyxoah S.A.
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2014-12
Primary Completion Date: 2015-11
Completion Date: 2016-04
First Posted: 2014-12-09
**Study Location(s):**
Antwerp University Hospital, Edegem, Belgium|Universitäts-HNO-Klinik Mannheim, Mannheim, Germany | |
**Title:** Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) (NCT04236479)
**Summary:** The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life
**Status:** ACTIVE_NOT_RECRUITING
Study Phase: PHASE1
**Conditions:** Congenital Heart Disease (CHD)
Intervention(s) Being Tested: BIOLOGICAL: BM-MSC
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations., Dose Limiting Toxicity is attributable to the MSC administration., 45 days following the MSC administration
The Secondary outcome measures of this study:
Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery., Secondary objective will be measured by using the Pediatric Cardiac Critical Care Consortium (PC4) registry system., 18 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 17.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Catherine Bollard
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2020-07-29
Primary Completion Date: 2024-09
Completion Date: 2025-04
First Posted: 2020-01-22
**Study Location(s):**
Childrens National Health System, Washington, District of Columbia, 20010, United States | |
**Title:** Oatmeal Effect on N-acyl-phosphatidylethanolamines (NCT03468179)
**Summary:** N-acyl-phosphatidylethanolamine (NAPEs) and their active metabolites, N-acyl-ethanolamides (NAEs) are lipid satiety factors that are normally biosynthesized in the intestinal tract in response to food intake. Reduced levels of NAPEs and NAEs have been found in obese individuals, and increasing plasma NAPE and NAEs levels may be beneficial to obese individuals trying to lose weight or to keep off weight gain after losing weight. We have found that oatmeal has large amounts of NAPEs, and based on previous mouse studies, we hypothesize that a single dose of dietary oatmeal is sufficient to double plasma NAE from baseline, possibly inducing satiety and increasing basal metabolic rate. To test this hypothesis, we will feed volunteers a single weight-based serving of oatmeal while monitoring its effects on serum glucose, NAPE and NAE levels as well as on subjective satiety.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Obesity|Cardiovascular Diseases
Intervention(s) Tested: DIETARY_SUPPLEMENT: Oatmeal
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Change in Serum N-acyl-phosphatidylethanolamine (NAPE), Change in serum NAPE from baseline to 120 minutes post-oatmeal challenge, Baseline to 120 minutes
The Secondary outcome measures of this study:
Serum NAPE, Serum NAPE Levels at 30, 60, and 90 minutes, 30, 60, and 90 minutes|Serum N-acyl-ethanolamides (NAE), Serum NAE levels at baseline, 30, 60, 90 and 120 minutes, baseline 30, 60, 90 and 120 minutes
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 10.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
**Study Sponsor(s):** Vanderbilt University Medical Center
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2018-10-07
Primary Completion Date: 2018-12-31
Completion Date: 2018-12-31
First Posted: 2018-03-16
**Study Location(s):**
Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States | |
**Title:** Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy (NCT02328079)
**Summary:** The purpose of this study is to assess the efficacy of antiviral medicine (acyclovir) in recovery of complete facial Palsy. Fifty patients (Males and females) with acute Facial Palsy within the first 3 days of onset with age ranged from 15-60 years old. Each patient was submitted to the following clinical evaluation using House and Brackmann 6 facial function scoring system and Synnybrook grading system. Neurophysiological assessment of facial nerve and muscles was done before and after the end of treatment, then after the end of first and second month of treatment. EMG was done for facial muscles of both sides beside measuring facial nerve excitability to determine the excitation threshold by recording the minimum electrical stimulus required to produce visible muscle contraction. A difference greater than 3.5 mA between the affected and unaffected side is considered significant in terms of poor prognosis. Nerve conduction study of facial nerves of both sides using concentric needle electrode. Trigeminal Blink reflex for both sides of the face. Facial functional recovery was defined as good or complete using the same criteria used in the 2001 practice guideline. An outcome of grade I or II was considered a good recovery using the House and Brackmann 6 facial function scoring system
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Facial Palsy
Intervention(s) Tested: DRUG: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Facial muscle function using clinical scale, Evaluations of facial muscle function using clinical scale were performed blindly by a neurologist who was unaware of the type of treatment of which the patient had received, 2 months
The Secondary outcome measures of this study:
Nerve conduction study of facial nerve., Measurment of facial n. coduction, 2 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD, ADULT
ii) Sex: ALL
**Enrollment:** 50.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Assiut University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2013-04
Primary Completion Date: 2014-11
Completion Date: 2014-11
First Posted: 2014-12-31
**Study Location(s):**
N/A | |
**Title:** Reproducibility of Ankle Brachial Index After Maximal Exercise (NCT01801579)
**Summary:** Hemodynamic changes in the lower limbs are very important and rapid after maximal exercise. The automatic method allows a fastest measurement of the Ankle-Brachial Index (ABI). Thus, it appears important to know whether automatic assessment of ABI is as reliable and reproducible as the manual method.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Normal Subjects
Intervention(s) Tested: N/A
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Test-retest difference in ankle to brachial pressure index, Comparison of differendces observed on test-retest measures with manual and automatic measurements, up to 2 week
The Secondary outcome measures of this study:
Duration of recordings., Comaprison of the time needed to complete the recording with automatic vs. manual techniques, up to 2 weeks
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT
ii) Sex: ALL
**Enrollment:** 15.0
**Funder Type:** OTHER_GOV
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** University Hospital, Angers
**Study Collaborator(s):** Institut de formation en éducation physique et en sport dAngers/Les Ponts de Cé
**Study Dates:**
Start Date: 2012-11
Primary Completion Date: 2014-04
Completion Date: 2014-04
First Posted: 2013-03-01
**Study Location(s):**
University Hospital, Angers, 49933, France | |
**Title:** Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy (NCT02854579)
**Summary:** The purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe Hypoxic-Ischemic Encephalopathy
**Status:** UNKNOWN
Study Phase: N/A
**Conditions:** Hypoxic-Ischemic Encephalopathy
Intervention(s) Being Tested: BIOLOGICAL: neural progenitor cell|BIOLOGICAL: Paracrine factors|BIOLOGICAL: progenitor cell and paracrine factors
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Neonatal Behavioral Neurological Assessment, 14days after birth|number of adverse events, adverse events like fever、infection、seizures、hemorrhage coursed by interventions, 7days after cell or factor injection|Neonatal Behavioral Neurological Assessment, 28days after birth
The Secondary outcome measures of this study:
Bayley score, Gross motor function measure assessment for children diagnosed cerebral palsy, 12 months after birth|Bayley score, Gross motor function measure assessment for children diagnosed cerebral palsy, 18 months after birth|Peabody development measure scale, Gross motor function measure assessment for children diagnosed cerebral palsy, 12 months after birth|Peabody development measure scale, Gross motor function measure assessment for children diagnosed cerebral palsy, 18 months after birth|Number of death, 1 years after birth|Number of participants with treatment-related central nervous tumor as assessed by Magnetic Resonance Imaging or CT, 5 years after birth
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 120.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Navy General Hospital, Beijing
**Study Collaborator(s):** Bethune International Peace Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Hunan Childrens Hospital|Shangluo Central Hospital|252 Military Hospital
**Study Dates:**
Start Date: 2013-01
Primary Completion Date: 2017-07
Completion Date: 2017-12
First Posted: 2016-08-03
**Study Location(s):**
Navy General Hospital, Beijing, Beijing, 100048, China|Navy General Hospital, Beijing, 100048, China | |
**Title:** Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1 (NCT02898779)
**Summary:** To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and SPQ and the racemic mixture RSPQ) in normal healthy human volunteers.
**Status:** COMPLETED
Study Phase: PHASE1
**Conditions:** Malaria
Intervention(s) Tested: DRUG: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Primary outcome: Plasma concentration of parent primaquine and carboyprimaquine following a single dose treatment with primaquine (racemate or enantiomers) not to exceed 45 mg, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 Hours
The Secondary outcome measures of this study:
Area Under Curve (AUC) for primaquine up to 24 hours after the primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 hours|Maximum concentration (Cmax) for primaquine up to 24 hours after the primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 hours|Area Under Curve (AUC) for carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 hours|Maximum concentration of carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 hours|Maximum concentration of selected metabolites primaquine (other than carboxyprimaquine) up to 24 hours after primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers. The exact nature of these metabolites will be determined from previous animal and human studies, between 0-24 hours|hemoglobin and methemoglobin levels in the blood after administration of primaquine, To monitor hemoglobin and methemoglobin levels in normal human volunteers treated with single dose of primaquine not to exceed 45 mg, 0-72 hours|Genotyping of Cytochrome P-450 (CYP), To determine correlation between metabolism of primaquine and CYP 2D6 genotype, day 0
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT
ii) Sex: ALL
**Enrollment:** 36.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE
**Study Sponsor(s):** University of Mississippi, Oxford
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2017-05-01
Primary Completion Date: 2018-03-01
Completion Date: 2018-03-01
First Posted: 2016-09-13
**Study Location(s):**
University of Mississippi, Oxford, Mississippi, 38677, United States | |
**Title:** A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects (NCT02840279)
**Summary:** This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the cognitive effects of BPN14770 in healthy elderly subjects.
**Status:** COMPLETED
Study Phase: PHASE1
**Conditions:** Alzheimers Disease
Intervention(s) Tested: DRUG: BPN14770|DRUG: Placebo
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Incidence and nature of adverse events (AEs) and serious adverse events (SAEs). Significant assessments reported as AEs or SAEs include clinical laboratory assessments and vital signs, physical and neurological examination, 12-lead electrocardiogram (ECG), 2 weeks
The Secondary outcome measures of this study:
Area Under the Curve from Time Zero to Twelve Hours [AUC0-12], 2 weeks|Area Under the Concentration Time Curve from Zero to 12 Hours, Corrected for Dose [AUC12/D], 2 weeks
Other Outcome Measures: ISLT-D, International Shopping List Test words recalled at 24 hours, 2 weeks|GMLT-D, Groton Maze Learning Test errors at 24 hours, 2 weeks
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 77.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** Tetra Discovery Partners
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2016-06
Primary Completion Date: 2016-11
Completion Date: 2016-12
First Posted: 2016-07-21
**Study Location(s):**
Jasper Clinic, Kalamazoo, Michigan, 49007, United States | |
**Title:** Double-Blind Naltrexone in Kleptomania (NCT00332579)
**Summary:** The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
**Status:** COMPLETED
Study Phase: PHASE2
**Conditions:** Kleptomania
Intervention(s) Tested: DRUG: Naltrexone|DRUG: Placebo
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS), The K-YBOCS measures symptom severity (urges/thoughts and behavior) across the past week. Scores range from 0 (no symptoms) to 40 (highest symptom severity)., K-YBOCS is done at each visit by the investigator.
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 25.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** University of Minnesota
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2006-05-01
Primary Completion Date: 2008-09-01
Completion Date: 2008-09-01
First Posted: 2006-06-01
**Study Location(s):**
University of Minnesota, Minneapolis, Minnesota, 55454, United States | |
**Title:** Observational Study of Hand Function After Distal Transradial Access for Angiography (NCT03789279)
**Summary:** Traditionally, coronary angiograms are performed through the radial artery which is accessed above the palm of the right hand. In recent years, some cardiologists are performing this procedure from the back of the wrist in as the radial artery courses through the anatomical snuffbox (distal radial access). The aim of this study is to determine the prevalence of hand dysfunction following coronary angiography via the distal radial artery.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Radial Artery Occlusion|Nerve Injury
Intervention(s) Tested: N/A
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Prevalence of hand dysfunction, Any significant deterioration from baseline in hand function according to the 5 studied domains., 1 month
The Secondary outcome measures of this study:
Success of distal radial access, Successful introduction of sheath, Day 0|Vascular access complications (other than occlusion and bleeding), Surgical complications or clinically important vascular access complications, Day 0|Puncture time, Time from skin puncture to successful placement of wire into the artery, Day 0|Radial artery occlusion - including level of occlusion (prox/distal), USS guide, 0-12 months|Fluoroscopy time, Minutes, Day 0|Hemostasis duration, Minutes, Day 0
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 40.0
**Funder Type:** OTHER
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** NHS National Waiting Times Centre Board
**Study Collaborator(s):** MC Zuiderzee
**Study Dates:**
Start Date: 2019-01-01
Primary Completion Date: 2020-12-31
Completion Date: 2020-12-31
First Posted: 2018-12-28
**Study Location(s):**
University of Glasgow/Golden Jubilee Research Foundation, Glasgow, G12 8QQ, United Kingdom | |
**Title:** Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety (NCT02588079)
**Summary:** The purpose of this study is to determine whether internet-based cognitive behavioral therapy (ICBT) is effective in the treatment of children and adolescents with dental anxiety. The investigators hypothesis is that children and adolescents who have been offered ICBT show significant better performance on outcome measures compared with patients in control group.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Dental Anxiety
Intervention(s) Tested: BEHAVIORAL: Internet-based cognitive behavioral therapy
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Picture guided behavioral approach test, child version, Measures changes in self-estimated ability to manage 17 dental situations, showing realistic images from dental care., post treatment(12 weeks), and follow up (12 months after posttreatment)|Picture guided behavioral approach test, parent version, Measures changes in the child´s ability to manage dental situations according to a parent. The test shows 17 realistic images from the dental care., post treatment(12 weeks), and follow up (12 months after posttreatment)
The Secondary outcome measures of this study:
Self-Efficacy Questionnaire for Phobic Situations ( dentistry adapted version ), Measure changes in childs dentistry related self efficacy, post treatment(12 weeks), and follow up (12 months after posttreatment)|Childrens Fear Survey Schedule - Dental Subscale (child version), Measures changes in the childs dental anxiety, post treatment(12 weeks), and follow up (12 months after posttreatment)|Childrens Fear Survey Schedule - Dental Subscale (parent version), Measures changes in the childs dental anxiety according to one of the parents, post treatment(12 weeks), and follow up (12 months after posttreatment)|Kiddie Sads (phobic disorders supplement), The phobic disorders supplement of Kiddie Sads diagnostic interview (Version 1.0 of October 1996) is performed by a psychologist through a telephone interview. The outcome is used to investigate whether the participant fulfill the diagnostic criteria for dentistry related specific phobia according to DSM 4., post treatment(12 weeks), and follow up (12 months after posttreatment)
Other Outcome Measures: Parental Self-Efficacy Questionnaire for Dental Anxiety, Measure changes in dentistry related parental self efficacy, post treatment(12 weeks), and follow up (12 months after posttreatment)|Childrens Negative Cognitions in Dentistry, Measure changes in childrens dentistry related negative thoughts., post treatment(12 weeks), and follow up (12 months after posttreatment)|Injection Phobia Scale for Children, Measure changes in childrens degree of anxiety related to injection, post treatment(12 weeks), and follow up (12 months after posttreatment)
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 33.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Karolinska Institutet
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2015-10
Primary Completion Date: 2023-12-31
Completion Date: 2023-12-31
First Posted: 2015-10-27
**Study Location(s):**
Department of Dental Medicine, Stockholm, Huddinge, 14104, Sweden | |
**Title:** Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation (NCT00717379)
**Summary:** To compare the efficacy and safety of Tacrolimus in combination with MMF and Steroids in two regimens of steroid in an adult kidney transplanted population.
**Status:** COMPLETED
Study Phase: PHASE4
**Conditions:** Kidney Transplantation|Kidney Failure, Chronic|Renal Insufficiency, Chronic
Intervention(s) Tested: DRUG: Tacrolimus|DRUG: Mycophenolate Mofetil|DRUG: Methylprednisolone or equivalent|DRUG: Prednisone
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Incidence and time to first biopsy-proven acute rejection, 6 months
The Secondary outcome measures of this study:
Overall frequency of acute rejection episodes within 6 months post transplantation, 6 months|Severity of biopsy proven acute rejections (BANFF criteria) within 6 months post transplantation, 6 months|Incidence of and time to first corticosteroid-resistant acute rejection, 6 months|Subject and graft survival, 6 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 50.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Astellas Pharma Inc
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2007-05
Primary Completion Date: 2008-10
Completion Date: 2008-10
First Posted: 2008-07-17
**Study Location(s):**
Moscow, 115446, Russian Federation|Moscow, 119992, Russian Federation|Moscow, 123182, Russian Federation|Omsk, 644112, Russian Federation|St. Petersburg, 197110, Russian Federation|Volzskii, 404120, Russian Federation | |
**Title:** Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkins Lymphoma (B-NHL) (NCT01294579)
**Summary:** The purpose of this phase II open label study was is to evaluate the safety and efficacy of ofatumumab and bendamustine followed by maintenance ofatumumab in subjects with indolent B-NHL who had relapsed after Rituximab treatment. A maximum of 53 subjects at least 18 years old with Small lymphocytic, lymphoplasmacytic, marginal zone lymphoma, or follicular lymphoma; Grades 1, 2 and 3a, would have been enrolled (34 in Stage 1 and 19 in Stage 2). Subjects should have had Rituximab-sensitive disease, defined as a Partial Remission (PR) or Complete Remission (CR) to the last rituximab-containing therapy lasting at least 6 months following completion of therapy or subjects should have relapsed or have had disease progression following response to prior rituximab-based therapy a Eastern Cooperative Oncology Group (ECOG) Performance status of 0 1 or 2. During the induction phase, ofatumumab 1000 mg IV on day 1 of each cycle (cycles 1-6) were followed by Bendamustine 90 mg/m2 IV on days 1, 2 of each cycle (cycles 1-6).During the maintenance phase, subjects with a PR or CR after the induction phase received ofatumumab 1000 mg IV every 2 months for 2 years.
**Status:** COMPLETED
Study Phase: PHASE2
**Conditions:** Lymphoma, Non-Hodgkin
Intervention(s) Tested: BIOLOGICAL: Ofatumumab|DRUG: Bendamustine
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS), Complete response (CR) included all of the following: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. All target nodes had to have regressed to ≤ 1.5cm in the longest diameter. Non-measureable nodes 1.1 to 1.5cm in the longest diameter and >1cm in the short axis at baseline had to regress to ≤ 1cm in the short axis by visual estimation; enlarged spleen or liver (with nodules) must have returned to normal size and nodules disappeared and if bone marrow was involved, infiltrate had to have cleared on repeat biopsy sample. CR was not valid without imaging data. The corresponding 2-sided 95% exact confidence interval (CI) of the response rate was estimated by the Clopper-Pearson method., Baseline up to 24 weeks
The Secondary outcome measures of this study:
Overall Response Rate (ORR) During Induction Phase After Cycle 6 (FAS), The overall response = CR (defined in Primary Outcome) + Partial Response (PR) which required all of the following: > or = to 50% decrease from baseline in target nodules; > or = to 50% decrease in hepatic/splenic nodules and no increase in liver or spleen size; no unequivocal progression in non-target lestions; no new sites of disease., Baseline up to 24 weeks|Conversion Rate of Partial Response in Induction Phase to Complete Response With Maintenance Ofatumumab (FAS), Rate of conversion from PR in the Induction phase, to CR with maintenance ofatumumab in subjects who have a PR with induction therapy with ofatumumab and bendamustine, Partial response in induction phase up to 24 weeks|Percentage of Participants With Progression Free Survival (PFS) up to 30 Months (FAS), Progression free survival (PFS) is defined as the interval between first treatment and disease progression or death due to any cause. PFS criteria: A previously normal node (≤ 1.5 x ≤ 1.0cm), including nodes that were not previously visible, must increase to >2.0 x ≥ 1.5cm; ≥ 50% increase from nadir in the PPD of any target node. The long axis must increase by at least 5 mm and to >2.0cm.; ≥ 50% increase from nadir in the long axis of any target node. The long axis must increase by at least 5 mm and to >2.0 cm.; ≥ 50% increase from nadir in the SPD of target nodes and at least one node should have a long axis >1.5 cm., Baseline up to approximately 30 months|Kaplan-Meier Estimates of Progression Free Survival up to 30 Months (FAS), Progression Free Survival (PFS) is defined as the interval between first treatment and disease progression or death due to any cause. PFS events: progression documented between scheduled visits, death before first PD assessment (or death at baseline or prior to any adequate assessments), death between adequate assessment visits. For the PFS analysis, the survival function was estimated using Kaplan-Meier estimates., Baseline up to approximately 30 months|Pharmacokinetic Profile Which Includes Measuring Blood Levels of Ofatumumab and Bendamustine in Combination and Ofatumumab Alone During Maintenance Treatment and Measuring Blood Levels of Circulating B Cell, Due to recruitment issues, this data analysis was not done per changes in planned analysis. This data was only presented as patient listings. The statistical analysis plan was modified to indicate that Pharmacokinetic/Pharmacodynamic exploratory analyses were not done., up to 30 months|All Deaths by Preferred Term (Safety Set) up to Approximately 30 Months, Deaths were collected and were considered to be an on treatment death up to 60 days post treatment., Baseline up to approximately 30 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 49.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Novartis Pharmaceuticals
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2011-05-17
Primary Completion Date: 2016-12-20
Completion Date: 2016-12-20
First Posted: 2011-02-11
**Study Location(s):**
Novartis Investigative Site, Chandler, Arizona, 85224, United States|Novartis Investigative Site, Burbank, California, 91505, United States|Novartis Investigative Site, Fresno, California, 93720, United States|Novartis Investigative Site, Oxnard, California, 93030, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Orange Park, Florida, 32073, United States|Novartis Investigative Site, Burlington, Massachusetts, 01805, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-9200, United States|Novartis Investigative Site, Las Vegas, Nevada, 89169, United States|Novartis Investigative Site, Cary, North Carolina, 27518, United States|Novartis Investigative Site, Charlotte, North Carolina, 28204, United States|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States|Novartis Investigative Site, Kettering, Ohio, 45429, United States|Novartis Investigative Site, Eugene, Oregon, 97401, United States|Novartis Investigative Site, Charleston, South Carolina, 29414, United States|Novartis Investigative Site, Greenville, South Carolina, 29601, United States|Novartis Investigative Site, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Sherman, Texas, 75090, United States|Novartis Investigative Site, Tyler, Texas, 75702, United States|Novartis Investigative Site, Waco, Texas, 76712, United States|Novartis Investigative Site, Vancouver, Washington, 98684, United States|Novartis Investigative Site, Yakima, Washington, 98902, United States | |
**Title:** Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (NCT05193279)
**Summary:** This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age.
**Status:** WITHDRAWN
Study Phase: PHASE2|PHASE3
**Conditions:** COVID-19
Intervention(s) Tested: BIOLOGICAL: Candidate vaccine, SCB-2019
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety, Proportion of subjects with solicited local and systemic adverse events, 7 days after dose 1 (Day 1-7)|Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety, Proportion of subjects with solicited local and systemic adverse events, 7 days after dose 2 (Day 22-28)|Phase 2, select optimal dose level of SCB-2019 vaccine in phase 2 by age cohort (5-11 years, 2-4 years, and < 2 years), based on immunogenicity, Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibody (nAb), Day 36|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years), GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to 12 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years), GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to 5 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years), GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to 2 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose
The Secondary outcome measures of this study:
Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years), Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to < 12 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose|Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years), Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to < 5 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose|Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years), Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to < 2 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study, 21/15 days after second SCB-2019 dose|In phase 2 and 3, GMT of SARS-CoV-2 nAb, Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, proportion of participants achieving seroconversion for SARS-CoV-2 nAb, Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, GMFR in SARS-CoV-2 nAb, Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, proportion of participants with SARS-CoV-2 nAb above a certain threshold, Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, GMT of SCB-2019 Binding Antibody, Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, proportion of participants achieving seroconversion for SCB-2019 binding antibody, Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, GMFR of SCB-2019 binding antibody, Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)|In phase 2 and 3, proportion of participants with SCB-2019 binding antibody above a certain threshold, Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)|In phase 3, reactogenicity of the vaccine as indicated by the occurrence of solicited local and systemic reactions, In phase 3, proportion of participants with local and systemic AEs, 7 days after dose 1 (Day 1-7), dose 2 (Day 22-Day 28) and Dose 3 (Day 43-49)|Phase 2 and 3, safety of the vaccine in terms of occurrence of unsolicited adverse events, Proportion of subjects with unsolicited adverse events, Up to 21 days after the last vaccination|Phase 2 and 3, safety of the vaccine in terms of occurrence of MAAEs, SAEs, adverse events leading to discontinuation from study, and AESIs., Proportion of participants with any adverse events in this category., During the entire study period
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 0.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
**Study Sponsor(s):** Clover Biopharmaceuticals AUS Pty Ltd
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2022-10-05
Primary Completion Date: 2022-12-15
Completion Date: 2022-12-15
First Posted: 2022-01-14
**Study Location(s):**
Clínica de la Costa Ltda, Barranquilla, 080020, Colombia|Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Cali, Colombia | |
**Title:** Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging (NCT00770679)
**Summary:** Cholesterol-lowering drugs called statins improve the functioning of the endothelium, and help prevent heart disease. The investigators are testing whether statins improve endothelial function more in the arteries that have worse endothelium to begin with. One of the functions of the endothelium is to help control how blood vessels dilate (expand) or contract (narrow) in different situations. This affects how blood flows through those vessels. Magnetic resonance imaging (MRI) can be used to evaluate endothelial function in the arms and legs noninvasively.
**Status:** TERMINATED
Study Phase: N/A
**Conditions:** Diabetes
Intervention(s) Tested: DRUG: lipitor
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Mean Change in Low Density Lipoprotein (LDL), Serum LDL, mg/dL (baseline LDL-follow-up LDL), Change from baseline to follow-up, up to 5 weeks|Change in Endothelial Function as Measured on MRI in the Arms, chance from baseline to end of study, up to 5 weeks|Change in Endothelial Function as Measured on MRI in the Legs, chance from baseline to end of study, up to 5 weeks
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 16.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
**Study Sponsor(s):** Johns Hopkins University
**Study Collaborator(s):** Pfizer
**Study Dates:**
Start Date: 2008-06
Primary Completion Date: 2012-07
Completion Date: 2012-07
First Posted: 2008-10-10
**Study Location(s):**
Harry SIlber, MD, Baltimore, Maryland, 21224, United States | |
**Title:** Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD (NCT01990079)
**Summary:** The primary goal of the study is to evaluate the use of a new smart phone application in preventing relapse to smoking among people with PTSD. The technology intervention will combine a mobile system to reward non-smoking, smoking cessation counseling, smoking cessation medications, and use of the smart phone app. The primary aim is to evaluate how effective this intervention is in preventing smoking relapse compared to another intervention that does not include the app.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** PTSD|Smoking
Intervention(s) Tested: DRUG: Bupropion|DRUG: nicotine replacement therapy|OTHER: Smoking cessation counseling|BEHAVIORAL: mobile contingency management|OTHER: Stay Quit Coach
**Outcome Measures of the Study:**
The primary outcome measures of this study:
smoking, self-report, Participants self-report of smoking in the past seven days will be measured at the end of the treatment intervention, and at 3 and 6-month follow-up contacts., 6 months follow-up
The Secondary outcome measures of this study:
saliva cotinine, For participants reporting smoking abstinence at 3 and 6-months post treatment follow-ups, we will bio-verify smoking abstinence by collecting saliva samples that will be used to determine salivary cotinine levels., 6 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 15.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Duke University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2013-12
Primary Completion Date: 2015-08
Completion Date: 2015-08
First Posted: 2013-11-21
**Study Location(s):**
Duke University Medical Center, Durham, North Carolina, 27706, United States | |
**Title:** PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers (NCT01180179)
**Summary:** The aim of this study is to compare the efficacy of a proton pump inhibitor (lansoprazole) and a histamine-2 receptor antagonist (famotidine) in preventing recurrent ulcer bleeding in patients with a history of H. pylori-negative idiopathic peptic ulcers.
**Status:** COMPLETED
Study Phase: PHASE4
**Conditions:** Peptic Ulcer
Intervention(s) Tested: DRUG: Lansoprazole|DRUG: Famotidine
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Recurrent ulcer bleeding, According to prespecified criteria - hematemesis or melena documented by the admitting physician, or a decrease in the hemoglobin level of at least 2 g/dL, with ulcers or bleeding erosions confirmed on endoscopy.
A prespecified interim-analysis is performed on the primary endpoint when all patients have been randomised and have completed the 12 months follow-up. The interim-analysis is performed by an independent statistician, blinded for the treatment allocation. The statistician will report to the independent data and safety monitoring committee (DSMC). The DSMC will have unblinded access to all data and will discuss the results of the interim-analysis with the steering committee in a joint meeting. The steering committee decides on the continuation of the trial and will report to the central ethics committee. The Peto approach is used: the trial will be ended using symmetric stopping boundaries at P < 0.001., 24 months
The Secondary outcome measures of this study:
Recurrent ulcer detected by endoscopy at 24-month, Recurrent ulcer detected by endoscopy at 24-month, with or without clinical symptoms., at the 24th month of follow-up
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 228.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
**Study Sponsor(s):** Chinese University of Hong Kong
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2010-06
Primary Completion Date: 2019-05
Completion Date: 2019-05
First Posted: 2010-08-12
**Study Location(s):**
Endoscopy Center, Prince of Wales Hospital, Shatin, Hong Kong, China | |
**Title:** Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome (NCT02680379)
**Summary:** The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.
**Status:** COMPLETED
Study Phase: PHASE2
**Conditions:** Fragile X Syndrome
Intervention(s) Tested: DRUG: Minocycline, then Minocycline/Lovastatin|DRUG: Lovastatin, then Minocycline/Lovastatin
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks, baseline, 8 weeks, 12 weeks, 20 weeks
The Secondary outcome measures of this study:
Clinical Global Impression Scale improvement (CGI-I), baseline, 8 weeks, 12 weeks, 20 weeks|Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks, baseline, 8 weeks, 20 weeks|Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks, baseline, 8 weeks, 20 weeks|Behavior Rating Inventory of Executive Function (BRIEF), Before treatment and at the end of treatment (weeks 20)|Change from baseline Vineland II; adaptive behaviour scale at 20 weeks, baseline, 20 weeks
Other Outcome Measures: (optional) Change in brain activity using Functional Magnetic Resonance Imaging (fMRI) at 8 and 20 weeks, fMRI is a non-invasive method of assessing brain activity by detecting signal changes in blood flow and oxygenation known as BOLD (Blood-Oxygen-Level Dependent) contrast imaging., baseline, 8 weeks, 20 weeks|(optional) Change in neurochemistry using Transcranial Magnetic Stimulation (TMS) at 8 and 20 weeks, Using an unpainful magnetic stimulation on the primary motor cortex, TMS will be used to assess intracortical facilitation and inhibition, corresponding respectively to glutamate and GABAergic processes., baseline, 8 weeks, 20 weeks
**Participant Details:**
i) Age: CHILD, ADULT
ii) Sex: ALL
**Enrollment:** 22.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Université de Sherbrooke
**Study Collaborator(s):** FRAXA Research Foundation
**Study Dates:**
Start Date: 2016-03
Primary Completion Date: 2017-10
Completion Date: 2017-11
First Posted: 2016-02-11
**Study Location(s):**
Centre de Recherche du CHUS, Sherbrooke, Quebec, J1H 5N4, Canada | |
**Title:** Digital-storytelling Intervention for Rural-dwelling Children (NCT04665479)
**Summary:** The overall purpose of this study is to test the feasibility of a web-based storytelling intervention for rural-dwelling children (ages 8-17) with serious advanced illnesses.
There is a growing need for home-based end-of-life and palliative care for children with serious illnesses. While palliative care interventions offered in home settings are significantly lacking, the problems are magnified by substantial gaps in access to palliative care for rural populations. Web-based recruitment and intervention methods have the potential to access hard-to-reach rural populations and provide a cost-effective health care. In particular, legacy-making (i.e., actions/behaviors aimed at being remembered) is one strategy to help decrease suffering and improve psychosocial outcomes for children with serious illness and end of life needs. Storytelling has successfully documented child legacies and may be an ideal format for children. Guided by our existing, web-based digital storytelling intervention and previous work, this project will offer a remotely-delivered legacy-making intervention to rural-dwelling children with diverse serious, advanced health conditions and their parents.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Pediatrics
Intervention(s) Tested: OTHER: Web-based legacy-making intervention through digital storytelling
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Change in PROMIS Pediatric Psychological Distress - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (always) to assess childrens psychological distress., Day 0, Day 43|Change in PROMIS Pediatric Anxiety - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (almost always) to assess childrens anxiety., Day 0, Day 43|Change in PROMIS Pediatric Depressive Symptom - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (almost always) to assess childrens depressive symptoms., Day 0, Day 43|Change in PROMIS Pediatric Meaning and Purpose - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (not at all) to 5 (very much) to assess childrens perception of meaning and purpose of life., Day 0, Day 43|Change in NIH Toolbox Perceived Stress Survey, A 10-item 5-point Likert scale measure ranging from 1 (never) to 5 (very often) to assess parents perceived stress in the past month., Day 0, Day 43|Change in PROMIS Anxiety - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (always) to assess parents anxiety., Day 0, Day 43|Change in PROMIS Depression- Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (always) to assess parents depression., Day 0, Day 43|Change in PROMIS Meaning and Purpose - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (strongly disagree) to 5 (strongly agree) to assess parents perception of meaning and purpose of life., Day 0, Day 43|Change in Parent-Adolescent Communication Scale, A 20-item 5-point Likert scale measure ranging from 1 (strongly disagree) to 5 (strongly agree) to assess quality of parent-adolescent communication., Day 0, Day 43|Change in PROMIS Pediatric Family Relationships - Short Form, A 8-item 5-point Likert scale measure ranging from 1 (never) to 5 (always) to assess childrens perception of family relationships., Day 0, Day 43|Satisfaction Survey, A 16-item survey to assess participants satisfaction of the intervention program. Ten 7-point Likert scale items assess satisfaction, and 6 items assess perceived benefits of the intervention., Day 43
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD
ii) Sex: ALL
**Enrollment:** 50.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE
**Study Sponsor(s):** Vanderbilt University
**Study Collaborator(s):** Rita & Alex Hillman Foundation
**Study Dates:**
Start Date: 2021-02-12
Primary Completion Date: 2022-06-30
Completion Date: 2022-12-31
First Posted: 2020-12-11
**Study Location(s):**
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States | |
**Title:** Tai Chi Exercise in Older People (NCT01039779)
**Summary:** The effects of tai chi exercise and lower-extremity training on improving the primary outcome and secondary outcomes among older people will be compared.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Fallers Aged 60 Years and Older
Intervention(s) Tested: BEHAVIORAL: Exercise
**Outcome Measures of the Study:**
The primary outcome measures of this study:
To ascertain the occurrence of falls, 18 months
The Secondary outcome measures of this study:
Fall-related outcomes of physical and psychological functions will assessed using direct interviews or performance tests at the subjects residence, 18 months
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 456.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
**Study Sponsor(s):** Taipei Medical University
**Study Collaborator(s):** National Health Research Institutes, Taiwan
**Study Dates:**
Start Date: 2011-01
Primary Completion Date: 2014-06
Completion Date: 2014-06
First Posted: 2009-12-25
**Study Location(s):**
Taipei Medical University, Taipei, 110, Taiwan | |
**Title:** BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. (NCT00545779)
**Summary:** This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Participants currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify participants who may benefit from a monthly Bonviva regimen. Eligible participants will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg per oral (po). At the beginning and end of Bonviva treatment, all participants will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
**Status:** COMPLETED
Study Phase: PHASE3
**Conditions:** Post-Menopausal Osteoporosis
Intervention(s) Tested: DRUG: Ibandronate
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Percentage of Participants Current Daily or Weekly Bisphosphonate Users in Part A Who Answer Yes to Any of the Questions in the Candidate Identification Questionnaire (CIQ), The CIQ was completed in Part A by all the participants. The information from the CIQ was used to determine the percentage of current daily or weekly bisphosphonate users for whom monthly ibandronate represented a potentially more satisfactory therapeutic option.
In the CIQ participants were asked to answer either yes or no to the following 3 questions:
1. I would prefer a monthly oral dosing schedule to my current (daily or weekly) dosing schedule.
2. More than once per month, I have experienced stomach upset within 48 hours of taking my osteoporosis medication.
3. Over the past 3 months, I have missed taking 3 or more doses of my current (daily or weekly) osteoporosis medication., Visit 0 (less than or equal to [<=] Day -30)|Percentage of Participants Who Reported Preference for Monthly Ibandronate, Percentage of participants who reported preference for monthly ibandronate were reported., Visit 0 (<= Day -30)|Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group, Participants with a positive change from their baseline CSS at Month 6 are considered those participants who are satisfied with once-monthly dosing of ibandronate after 6 months of use were reported. The CSS is scaled from 0 to 100 and is an average of the 4 domain scores of the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q): Convenience (questions 1 to 6), Quality of Life (questions 7 and 8), Overall Satisfaction (questions 9 and 10) and Side Effects (questions 11 to 16). Higher scores indicating greater satisfaction., Month 6
The Secondary outcome measures of this study:
Percentage of Participants Eligible Current Daily or Weekly Bisphosphonate Users at Screening Who Elect to Enter Part B by CIQ, Visit 0 (<= Day -30)|Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B, Percentage of participants who report an improved satisfaction score after 6 months of monthly ibandronate therapy as compared to daily or weekly alendronate or risendronate at baseline based on responses to each individual question in the CIQ were reported. In the CIQ participants were asked to answer either yes or no to the following 3 questions:
1. I would prefer a monthly oral dosing schedule to my current (daily or weekly) dosing schedule
2. More than once per month, I have experienced stomach upset within 48 hours of taking my osteoporosis medication
3. Over the past 3 months, I have missed taking 3 or more doses of my current (daily or weekly) osteoporosis medication, Month 6|Percentage of Participants Who Have Greater Than or Equal to (>=) 80% Compliance With 6 Monthly Doses of Ibandronate in Part B, Up to Month 6|Percentage of Participants Who Choose a Monthly Reminder to Take Ibandronate in Part B, Visit 0 (<= Day -30)|Percentage of Participants Who Reported an Improvement in the Frequency of Gastro-intestinal (GI) Symptoms Per Month in Part B, Baseline to Month 6|Percentage of Participants by Age and Activity Level Reporting High Satisfaction According to the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) in Part B, Month 6|Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B, The OPSAT-Q is a validated questionnaire designed to capture satisfaction with bisphosphonate treatment. It comprises four domains: convenience (questions 1-6), quality of life (questions 7 and 8), overall satisfaction (questions 9 and 10), and side effects (questions 11-16). Each domain (scale) ranges 0-100 scale. All items were scored such that higher scores represented greater satisfaction or less bother. Treatment satisfaction was measured with the OPSAT-Q composite satisfaction score (OPSAT-Q CSS), which was the average of the scores from the four domains of the OPSAT-Q converted to a 0-100-point scale, in which higher scores indicate greater satisfaction., Baseline, Month 6
Other Outcome Measures: N/A
**Participant Details:**
i) Age: CHILD, ADULT, OLDER_ADULT
ii) Sex: FEMALE
**Enrollment:** 677.0
**Funder Type:** INDUSTRY
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
**Study Sponsor(s):** Hoffmann-La Roche
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2006-12
Primary Completion Date: 2008-10
Completion Date: 2008-10
First Posted: 2007-10-17
**Study Location(s):**
Tirana, Albania|Banja Luka, 78000, Bosnia and Herzegovina|Sarajevo, 71 000, Bosnia and Herzegovina|Sarajevo, 71000, Bosnia and Herzegovina|Tuzla, 75000, Bosnia and Herzegovina|Rijeka, 51000, Croatia|Slavonski Brod, 35000, Croatia|Split, 21000, Croatia|Zagreb, 10000, Croatia|Skopje, Macedonia, The Former Yugoslav Republic of|Belgrade, 11000, Serbia|Niska Banja, 18205, Serbia|Novi Sad, 21000, Serbia|Adana, 01330, Turkey|Ankara, 06100, Turkey|Ankara, 06550, Turkey|Antalya, 07070, Turkey|Aydin, 09100, Turkey|Bursa, 16059, Turkey|Denizli, 20020, Turkey|Erzurum, 25240, Turkey|Gaziantep, 27310, Turkey|Istanbul, 34300, Turkey|Istanbul, 34303, Turkey|Istanbul, 35340, Turkey|Istanbul, 81190, Turkey|Izmir, 35100, Turkey|Kayseri, 38039, Turkey|Konya, 42080, Turkey|Manisa, 45200, Turkey|Samsun, 55139, Turkey|Trabzon, 61080, Turkey | |
**Title:** Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy (NCT04138979)
**Summary:** To date, few studies have addressed the link between gut microbiota and breast cancer chemotherapy, and previous studies have only provided a link between the gut and breast cancer.
**Status:** UNKNOWN
Study Phase: N/A
**Conditions:** Microbiota
Intervention(s) Being Tested: DRUG: cyclophosphamide
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Transcriptional changes in gut microbiota, The microbiota measured by 16S rRNA gene, baseline,1 day,7 day,14 days,22 days,29 days,36 days,44days,51days,58days,66days,73days,80days
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: FEMALE
**Enrollment:** 80.0
**Funder Type:** OTHER
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** First Affiliated Hospital of Harbin Medical University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-09-12
Primary Completion Date: 2020-10-15
Completion Date: 2020-10-15
First Posted: 2019-10-25
**Study Location(s):**
First affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | |
**Title:** Bariatric Surgery and Pharmacokinetics of Escitalopram (NCT03460379)
**Summary:** Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.
**Status:** RECRUITING
Study Phase: N/A
**Conditions:** Obesity, Morbid
Intervention(s) Being Tested: DRUG: Escitalopram
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Escitalopram concentration in blood serum (area under curve (AUC)), From baseline to 1 year postoperatively
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 12.0
**Funder Type:** OTHER
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** Norwegian University of Science and Technology
**Study Collaborator(s):** St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital
**Study Dates:**
Start Date: 2016-11-02
Primary Completion Date: 2026-10
Completion Date: 2026-10
First Posted: 2018-03-09
**Study Location(s):**
St. Olavs University Hospital, Trondheim, Norway | |
**Title:** Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS (NCT00372879)
**Summary:** Muscular cramps are a common and uncomfortable symptom of amyotrophic lateral sclerosis (ALS). This clinical trial will compare the response of high dose vitamin E supplementation to placebo for treatment of muscular cramps in patients with ALS. We hypothesize that vitamin E will be more effective than placebo in treating cramps.
**Status:** COMPLETED
Study Phase: PHASE3
**Conditions:** Amyotrophic Lateral Sclerosis
Intervention(s) Tested: DIETARY_SUPPLEMENT: Vitamin E
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Reduction in number of muscle cramps experienced in a two week period., 4 weeks
The Secondary outcome measures of this study:
Reduction in the duration of cramps and reduction in the severity of cramps, 4 weeks
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 32.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** Lawson Health Research Institute
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2006-12
Primary Completion Date: 2010-08
Completion Date: 2010-08
First Posted: 2006-09-07
**Study Location(s):**
London Health Sciences Centre, London, Ontario, N6A 5A5, Canada | |
**Title:** Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients (NCT02399579)
**Summary:** The purpose of this study is to better standardize the symptom recording of cat allergic persons under real-life conditions. A new self-assessed, home-based symptom score will be tested.
**Status:** COMPLETED
Study Phase: N/A
**Conditions:** Cat Allergy
Intervention(s) Tested: OTHER: Provocation test
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Time until the participant becomes symptomatic, How long can the owner pet his/her cat until he becomes symptomatic?, approx. 15 minutes (during Provocation Test)
The Secondary outcome measures of this study:
Number of score points resulting from symptom score recording before and after the provocation test., approx. 15 minutes (before and after provocation)|Visual Analogue Scale Values, approx. 5 minutes (before provocation)
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 10.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:
**Study Sponsor(s):** University of Zurich
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2015-03
Primary Completion Date: 2015-06
Completion Date: 2015-06
First Posted: 2015-03-26
**Study Location(s):**
Clinical Trial Center of the University Hospital Zurich, Zurich, 8091, Switzerland | |
**Title:** Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit (NCT05357079)
**Summary:** This multi-center, prospective study will evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.
**Status:** RECRUITING
Study Phase: EARLY_PHASE1
**Conditions:** Fracture of Posterior Wall of Acetabulum
Intervention(s) Being Tested: DRUG: Tranexamic Acid|DRUG: Normal saline
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Hemoglobin (Hb), Hemoglobin (Hb) results, Postoperative Day 2|Hematocrit (Hct), Hematocrit (Hct) results, Postoperative Day 2
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 98.0
**Funder Type:** OTHER
**Study Type:** INTERVENTIONAL
**Study Design:** Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
**Study Sponsor(s):** University of Cincinnati
**Study Collaborator(s):** Foundation for Orthopedic Trauma
**Study Dates:**
Start Date: 2017-08-25
Primary Completion Date: 2025-08-30
Completion Date: 2025-12-30
First Posted: 2022-05-02
**Study Location(s):**
University of Cincinnati College of Medicine, Cincinnati, Ohio, 45267, United States | |
**Title:** Impact of Different Dietary IgGs on the Pathogenesis of IBD (NCT03885479)
**Summary:** Identify the association between certain food IgGs (Wheat, rice, broad beans, cow milk, eggs, chicken and beef) and the immunological response in patients with IBD
**Status:** UNKNOWN
Study Phase: N/A
**Conditions:** Inflammatory Bowel Diseases|Food Intolerance
Intervention(s) Being Tested: DIAGNOSTIC_TEST: ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens
**Outcome Measures of the Study:**
The primary outcome measures of this study:
Level of serum food specific IgGs in patients with IBD, Level of serum food specific IgGs in patients with Inflammatory bowel diseasea against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef), baseline
The Secondary outcome measures of this study:
N/A
Other Outcome Measures: N/A
**Participant Details:**
i) Age: ADULT, OLDER_ADULT
ii) Sex: ALL
**Enrollment:** 150.0
**Funder Type:** OTHER
**Study Type:** OBSERVATIONAL
**Study Design:** Observational Model: |Time Perspective: p
**Study Sponsor(s):** Assiut University
**Study Collaborator(s):** N/A
**Study Dates:**
Start Date: 2019-04-01
Primary Completion Date: 2019-12-31
Completion Date: 2020-03-31
First Posted: 2019-03-21
**Study Location(s):**
N/A |
End of preview. Expand
in Dataset Viewer.
No dataset card yet
New: Create and edit this dataset card directly on the website!
Contribute a Dataset Card- Downloads last month
- 3